Pfizer (PFE) 10-Q 9 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 06, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	PFIZER INC
Entity Central Index Key	0000078003
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Emerging Growth Company	false
Entity Small Business	false
Trading Symbol	PFE
Entity Common Stock, Shares Outstanding		5,559,929,190

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Income Statement [Abstract]
Revenues	[1]	$ 13,118	$ 12,906
Costs and expenses:
Cost of sales	[1],[2]	2,433	2,563
Selling, informational and administrative expenses	[1],[2]	3,339	3,412
Research and development expenses	[1],[2]	1,703	1,743
Amortization of intangible assets	[1]	1,183	1,196
Restructuring charges and certain acquisition-related costs	[1]	46	43
Other (income)/deductions––net	[1]	92	(178)
Income from continuing operations before provision for taxes on income	[1],[3]	4,323	4,127
Provision for taxes on income	[1]	433	556
Income from continuing operations	[1]	3,889	3,571
Discontinued operations––net of tax	[1]	0	(1)
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	3,889	3,570
Less: Net income attributable to noncontrolling interests	[1]	6	9
Net income attributable to Pfizer Inc.	[1]	$ 3,884	$ 3,561
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.69	$ 0.60
Discontinued operations––net of tax (in dollars per share)	[1]	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.69	0.60
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.68	0.59
Discontinued operations––net of tax (in dollars per share)	[1]	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.68	$ 0.59
Weighted-average shares––basic	[1]	5,635	5,957
Weighted-average shares––diluted	[1]	5,750	6,057
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $64 million in the first quarter of 2019 and $59 million in the first quarter of 2018 from our investment in ViiV. For additional information, see Note 4.
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 3,889	$ 3,570
Foreign currency translation adjustments, net	[2]	324	758
Reclassification adjustments	[2]	2	15
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	[2]	326	773
Unrealized holding gains/(losses) on derivative financial instruments, net	[2]	267	(114)
Reclassification adjustments for (gains)/losses included in net income	[2],[5]	(263)	44
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[2]	4	(69)
Unrealized holding gains on available-for-sale securities, net	[2]	40	160
Reclassification adjustments for (gains)/losses included in net income	[2],[5]	11	(174)
Reclassification adjustments for unrealized gains included in Retained Earnings	[2],[6]	0	(462)
Other comprehensive income (loss), available-for-sale securities, before tax, total	[2]	51	(476)
Benefit plans: actuarial gains, net	[2]	0	163
Reclassification adjustments related to amortization	[2]	60	62
Reclassification adjustments related to settlements, net	[2]	0	37
Other	[2]	(23)	(86)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[2]	37	175
Reclassification adjustments related to amortization of prior service costs and other, net	[2]	(46)	(46)
Reclassification adjustments related to curtailments of prior service costs and other, net	[2]	0	(7)
Other	[2]	0	2
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[2]	(46)	(51)
Other comprehensive income, before tax	[2]	372	352
Tax provision on other comprehensive income	[2]	25	432
Other comprehensive income/(loss) before allocation to noncontrolling interests	[2],[4]	348	(80)
Comprehensive income before allocation to noncontrolling interests	[2]	4,237	3,490
Less: Comprehensive income attributable to noncontrolling interests	[2]	1	10
Comprehensive income attributable to Pfizer Inc.	[2]	$ 4,236	$ 3,480
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
[6]	For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	[1]	$ 1,937	$ 1,139	[2]
Short-term investments	[1]	9,682	17,694
Trade accounts receivable, less allowance for doubtful accounts: 2019—$538; 2018—$541	[1]	9,599	8,025
Inventories	[1],[3]	8,029	7,508
Current tax assets	[1]	3,598	3,374
Other current assets	[1]	2,567	2,461
Assets held for sale	[1]	9,877	9,725
Total current assets	[1]	45,290	49,926
Long-term investments	[1]	2,859	2,767
Property, plant and equipment, less accumulated depreciation: 2019—$16,158; 2018—$16,591	[1]	13,467	13,385
Identifiable intangible assets, less accumulated amortization	[1],[4]	34,039	35,211
Goodwill	[1]	53,487	53,411
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,946	1,924
Other noncurrent assets	[1]	4,333	2,799
Total assets	[1]	155,421	159,422
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2019—$4,471; 2018—$4,776	[1]	9,410	8,831
Trade accounts payable	[1]	4,156	4,674
Dividends payable	[1]	0	2,047
Income taxes payable	[1]	1,849	1,265
Accrued compensation and related items	[1]	1,797	2,397
Other current liabilities	[1]	10,276	10,753
Liabilities held for sale	[1]	1,935	1,890
Total current liabilities	[1]	29,423	31,858
Long-term debt	[1]	35,733	32,909
Pension benefit obligations, net	[1]	5,125	5,272
Postretirement benefit obligations, net	[1]	1,332	1,338
Noncurrent deferred tax liabilities	[1]	3,591	3,700
Other taxes payable	[1]	14,712	14,737
Other noncurrent liabilities	[1]	6,346	5,850
Total liabilities	[1]	96,263	95,664
Commitments and Contingencies	[1]
Preferred stock	[1]	19	19
Common stock	[1]	468	467
Additional paid-in capital	[1]	86,635	86,253
Treasury stock	[1]	(110,781)	(101,610)
Retained earnings	[1]	93,388	89,554
Accumulated other comprehensive loss	[1]	(10,923)	(11,275)
Total Pfizer Inc. shareholders’ equity	[1]	58,806	63,407
Equity attributable to noncontrolling interests	[1]	352	351
Total equity	[1],[5]	59,158	63,758
Total liabilities and equity	[1]	$ 155,421	$ 159,422
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery and market demand.
[4]	The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization and intangible asset impairment charges, partially offset by additions for the period. See Note 4 for additional information on intangible asset impairments.
[5]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	[1]	$ 538	$ 541
Property, plant and equipment, accumulated depreciation	[1]	16,158	16,591
Current portion of long-term debt	[1]	$ 4,471	$ 4,776
[1]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Millions		Total		Preferred Stock [Member]		Common Stock [Member]		Add'l Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accum. Other Comp. Loss [Member]	Parent [Member]		Noncontrolling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2017	[1]			524		9,275,000,000			3,296,000,000
Beginning balance at Dec. 31, 2017	[1]	$ 71,656		$ 21		$ 464		$ 84,278	$ (89,425)	$ 85,291	$ (9,321)	$ 71,308		$ 348
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	3,570	[2],[3],[4]							3,561		3,561		9
Other comprehensive income/(loss), net of tax	[1]	(80)	[3]								(81)	(81)		1
Cash dividends declared:
Common stock	[1]	(65)								(65)		(65)
Preferred stock	[1]	0								0		0
Noncontrolling interests	[1]	0												0
Share-based payment transactions (in shares)						24,000,000	[1]		3,000,000
Share-based payment transactions	[1]	351				$ 1		321	$ 29			351
Purchases of common stock (in shares)	[1]								(145,000,000)
Purchases of common stock	[1]	(6,063)							$ (6,063)			(6,063)
Preferred stock conversions and redemptions (in shares)	[1]			(11)
Preferred stock conversions and redemptions	[1]	(1)						(1)				(1)
Other	[1],[5]	1,175								1,175		1,175
Ending balance (in shares) at Apr. 01, 2018				513	[1]	9,299,000,000	[1]		3,437,000,000
Ending balance at Apr. 01, 2018	[1]	70,541		$ 21		$ 465		84,599	$ (95,460)	89,961	(9,402)	70,184		358
Beginning balance (in shares) at Dec. 31, 2018				478		9,332,000,000			3,615,000,000
Beginning balance at Dec. 31, 2018	[1]	63,758	[6]	$ 19		$ 467		86,253	$ (101,610)	89,554	(11,275)	63,407		351
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	3,889	[2],[3],[4]							3,884		3,884		6
Other comprehensive income/(loss), net of tax	[1]	348	[3]								353	353		(4)
Cash dividends declared:
Common stock	[1]	(68)								(68)		(68)
Preferred stock	[1]	0								0		0
Noncontrolling interests	[1]	0												0
Share-based payment transactions (in shares)						26,000,000			(7,000,000)
Share-based payment transactions	[1]	78				$ 1		383	$ (306)			78
Purchases of common stock (in shares)									(180,000,000)
Purchases of common stock		(8,865)										(8,865)	[1]
Preferred stock conversions and redemptions (in shares)				(12)
Preferred stock conversions and redemptions	[1]	(1)						(1)				(1)
Other	[1],[7]	19								19		19
Ending balance (in shares) at Mar. 31, 2019				466		9,358,000,000			3,801,000,000
Ending balance at Mar. 31, 2019	[1]	$ 59,158	[6]	$ 19		$ 468		$ 86,635	$ (110,781)	$ 93,388	$ (10,923)	$ 58,806		$ 352
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Represents the cumulative effect of the adoption of new accounting standards in the first quarter of 2018 for revenues, financial assets and liabilities, income tax accounting, and the reclassification of certain tax effects from Accumulated other comprehensive income. For additional information, see Notes to Consolidated Financial Statements––Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in Pfizer’s 2018 Financial Report.
[6]	Amounts may not add due to rounding.
[7]	Represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 3,889	$ 3,570
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[1]	1,545	1,567
Asset write-offs and impairments	[1]	155	7
TCJA impact	[1],[5]	(131)	(68)
Deferred taxes from continuing operations	[1]	(60)	294
Share-based compensation expense	[1]	185	182
Benefit plan contributions in excess of expense	[1]	(151)	(692)
Other adjustments, net	[1]	(236)	(161)
Other changes in assets and liabilities, net of acquisitions and divestitures	[1]	(3,498)	(2,715)
Net cash provided by operating activities	[1]	1,698	1,983
Investing Activities
Purchases of property, plant and equipment	[1]	(460)	(386)
Purchases of short-term investments	[1]	(1,402)	(913)
Proceeds from redemptions/sales of short-term investments	[1]	3,601	6,463
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[1]	5,941	4,507
Purchases of long-term investments	[1]	(84)	(605)
Proceeds from redemptions/sales of long-term investments	[1]	44	576
Acquisitions of intangible assets	[1]	(158)	(32)
Other investing activities, net	[1]	67	57
Net cash provided by investing activities	[1]	7,550	9,667
Financing Activities
Proceeds from short-term borrowings	[1]	609	428
Principal payments on short-term borrowings	[1]	(1,766)	(2,493)
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less	[1]	2,032	(83)
Proceeds from issuance of long-term debt	[1]	4,942	0
Principal payments on long-term debt	[1]	(3,004)	(355)
Purchases of common stock	[1]	(8,865)	(6,063)
Cash dividends paid	[1]	(2,045)	(2,032)
Proceeds from exercise of stock options	[1]	126	372
Other financing activities, net	[1]	(495)	(495)
Net cash used in financing activities	[1]	(8,467)	(10,720)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	[1]	12	55
Net increase in cash and cash equivalents and restricted cash and cash equivalents	[1]	792	985
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[1]	1,225	1,431
Cash and cash equivalents and restricted cash and cash equivalents, end	[1]	2,018	2,416
Cash paid (received) during the period for:
Income taxes	[1]	235	257
Interest paid	[1]	385	259
Interest rate hedges	[1]	$ (33)	$ 20
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision for taxes on income for (i) the three months ended March 31, 2019 was favorably impacted by approximately $131 million, primarily as a result of additional guidance issued by the U.S. Department of Treasury and (ii) the three months ended April 1, 2018 was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Statement of Cash Flows [Abstract]
TCJA benefit	[1],[2]	$ 131	$ 68
[1]	Amounts may not add due to rounding.
[2]	As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision for taxes on income for (i) the three months ended March 31, 2019 was favorably impacted by approximately $131 million, primarily as a result of additional guidance issued by the U.S. Department of Treasury and (ii) the three months ended April 1, 2018 was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three months ended February 24, 2019 and February 25, 2018 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three months ended March 31, 2019 and April 1, 2018 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2018 Financial Report. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13 . Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. In the first quarter of 2019 , as of January 1, 2019 , we adopted four new accounting standards. See Note 1B for further information. Our recent significant business development activities include: • On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture, which will operate globally under the GSK Consumer Healthcare name. Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheets as of March 31, 2019 and December 31, 2018. We expect to complete the transaction during the second half of 2019, subject to customary closing conditions, including GSK shareholder approval, which occurred on May 8, 2019, and required regulatory approvals. For additional information, see Note 2 and Notes to Consolidated Financial Statements–– Note 2. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment in Pfizer’s 2018 Financial Report. B. Adoption of New Accounting Standards On January 1, 2019, we adopted four new accounting standards. Leases ––On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of $1.4 billion and current and noncurrent operating lease liabilities of $1.4 billion as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $30 million on a pre-tax basis ( $20 million after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules. Adopting the standard related to leases impacted our prior period condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2018 Effect of Change Higher/(Lower) Balance at January 1, 2019 Other current assets $ 2,461 $ (1 ) $ 2,460 Noncurrent deferred tax assets and other noncurrent tax assets 1,924 (11 ) 1,913 Other noncurrent assets 2,799 1,351 4,149 Other current liabilities 10,753 258 11,011 Other noncurrent liabilities 5,850 1,060 6,910 Retained earnings 89,554 20 89,574 Adoption of the standard related to leases did not have a material impact on our condensed consolidated statements of income or condensed consolidated statements of cash flows for the quarter ended March 31, 2019 . For additional information, see Note 1D . Amortization Period for Certain Callable Debt Securities Held at a Premium ––We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features ––We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Share-Based Payments to Nonemployees ––We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. On January 1, 2018, we adopted eleven new accounting standards. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 included in our 2018 Financial Report. C. Revenues and Trade Accounts Receivable Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.5 billion as of March 31, 2019 and $5.4 billion as of December 31, 2018 . The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,232 $ 1,288 Other current liabilities : Accrued rebates 3,344 3,208 Other accruals 559 531 Other noncurrent liabilities 410 399 Total accrued rebates and other accruals $ 5,544 $ 5,426 D. Leases On January 1, 2019, we adopted a new accounting standard for leases. For further information, see Note 1B . We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $59 million for the three months ended March 31, 2019 . We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes. We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. For operating leases, the ROU assets and liabilities are presented in our condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) Balance Sheet Classification Balance at March 31, 2019 ROU assets Other noncurrent assets $ 1,280 Lease liabilities (short-term) Other current liabilities 253 Lease liabilities (long-term) Other noncurrent liabilities 1,043 Our total lease costs are as follows: Three Months Ended (MILLIONS OF DOLLARS) March 31, 2019 Operating lease cost $ 100 Variable lease cost 59 Sublease income (10 ) Total lease cost $ 149 Other supplemental information includes the following: (MILLIONS OF DOLLARS) Weighted-Average Remaining Contractual Lease Term (Years) Three Months Ended March 31, 2019 Operating leases 7.5 Weighted-average discount rate: Operating leases 3.7 % Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 78 ROU assets obtained in exchange for new operating lease liabilities 46 The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of March 31, 2019: (MILLIONS OF DOLLARS) Period Operating Lease Liabilities Next one year (a) $ 287 1-2 years 241 2-3 years 207 3-4 years 175 4-5 years 144 Thereafter 435 Total undiscounted lease payments 1,489 Less: Imputed interest 193 Present Value of Minimum Lease Payments 1,296 Less: Current portion 253 Noncurrent portion $ 1,043 (a) Reflects lease payments due within 12 months subsequent to the balance sheet date. In April 2018, we entered an agreement to lease space in an office building in New York City. We will relocate our global headquarters to this property with commencement expected in 2022. Our future minimum rental commitment under this 20 -year lease is approximately $1.7 billion . Prior to our adoption of the new lease standard, rental expense, net of sublease income, was $301 million in 2018, $314 million in 2017 and $292 million in 2016. As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2019 2020 2021 2022 2023 After 2023 Lease commitments $ 300 $ 252 $ 210 $ 267 $ 248 $ 2,040

Assets and Liabilities Held for

Assets and Liabilities Held for Sale	3 Months Ended
	Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Held for Sale	Assets and Liabilities Held for Sale On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business, we will receive a 32% equity stake in the new company and GSK will own the remaining 68% . The transaction is expected to close in the second half of 2019, subject to customary closing conditions, including GSK shareholder approval, which occurred on May 8, 2019, and required regulatory approvals. Upon the closing of the transaction, we will deconsolidate our Consumer Healthcare business and recognize a gain for the difference in the fair value of our 32% equity stake in the new company and the carrying value of our Consumer Healthcare business. We will account for our 32% equity stake in the new company after closing of the transaction as an equity-method investment. Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheets as of March 31, 2019 and December 31, 2018. The Consumer Healthcare business assets held for sale are reported in Assets held for sale and Consumer Healthcare business liabilities held for sale are reported in Liabilities held for sale . This includes the Consumer Healthcare business tax assets and liabilities related to fully dedicated consumer healthcare subsidiaries. The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Assets Held for Sale Cash and cash equivalents $ 61 $ 32 Trade accounts receivable, less allowance for doubtful accounts 550 532 Inventories 563 538 Other current assets 57 56 PP&E 687 675 Identifiable intangible assets, less accumulated amortization 5,776 5,763 Goodwill 1,972 1,972 Noncurrent deferred tax assets and other noncurrent tax assets 59 54 Other noncurrent assets 105 57 Total Consumer Healthcare assets held for sale 9,830 9,678 Other assets held for sale (a) 47 46 Assets held for sale $ 9,877 $ 9,725 Liabilities Held for Sale Trade accounts payable $ 335 $ 406 Income taxes payable 55 39 Accrued compensation and related items 140 93 Other current liabilities 371 353 Pension benefit obligations, net 39 39 Postretirement benefit obligations, net 33 33 Noncurrent deferred tax liabilities 884 870 Other noncurrent liabilities 78 56 Total Consumer Healthcare liabilities held for sale $ 1,935 $ 1,890 (a) Other assets held for sale consist of PP&E. As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was $281 million for the three months ended March 31, 2019 and $265 million for the three months ended 2018.

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	3 Months Ended
	Mar. 31, 2019
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. 2017-2019 Initiatives and Organizing for Growth During 2018, as we reviewed our business opportunities and challenges and the way in which we think about our business operations, we determined that at the start of our 2019 fiscal year, we would begin operating under our new commercial structure, which reorganizes our operations into three businesses –– Biopharma, a science-based innovative medicines business; Upjohn, a global, primarily off-patent branded and generic established medicines business; and a Consumer Healthcare business (see Note 13 ). To operate effectively in this structure and position ourselves for future growth, we are focused on creating a simpler, more efficient operating structure within each business as well as the functions that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new structure and combined the 2017-2019 initiatives with our current Organizing for Growth initiatives to form one cohesive plan. Initiatives for the combined program include activities related to the optimization of our manufacturing plant network, the centralization of our corporate and platform functions, and the simplification and optimization of our operating business structure and functions that support them. Through March 31, 2019 , we incurred approximately $735 million associated with manufacturing optimization, and approximately $793 million associated with other activities. In 2019, we expect restructuring, implementation and additional depreciation charges of about $800 million and, of that amount, we expect approximately 20% of the total charges will be non-cash. Current-Period Key Activities For the first three months of 2019 , we incurred costs of $92 million composed of $64 million associated with the 2017-2019 and Organizing for Growth initiatives, $25 million associated with the integration of Hospira and $3 million associated with all other acquisition-related initiatives. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended (MILLIONS OF DOLLARS) March 31, April 1, Restructuring charges/(credits): Employee terminations $ (2 ) $ (8 ) Asset impairments 9 2 Exit costs 3 (3 ) Restructuring charges/(credits) (a) 10 (9 ) Integration costs (b) 36 52 Restructuring charges and certain acquisition-related costs 46 43 Net periodic benefit costs recorded in Other (income)/deductions––net 6 32 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (c) : Cost of sales 9 17 Selling, informational and administrative expenses 1 — Research and development expenses 3 — Total additional depreciation––asset restructuring 13 17 Implementation costs recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 13 16 Selling, informational and administrative expenses 9 17 Research and development expenses 4 6 Total implementation costs 26 39 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 92 $ 131 (a) In the first quarter of 2019 , restructuring charges are primarily associated with cost reduction initiatives and mainly represent asset write downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. In the three months ended April 1, 2018 , restructuring credits were primarily due to the reversal of previously recorded accruals for exit costs related to our acquisition of Hospira, as well as cost-reduction and productivity initiatives not associated with acquisitions. The restructuring activities for the three months ended March 31, 2019 are associated with the following: • Biopharma ( $13 million charge ); Upjohn ( $13 million credit ); and Other ( $10 million charge). The restructuring activities for the three months ended April 1, 2018 are associated with the following: • Total reportable segments ( $14 million credit); and Other ( $4 million charge). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments. (b) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the first quarter of 2019 and 2018, integration costs were primarily related to our acquisition of Hospira. (c) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (d) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2018 (a) $ 1,203 $ — $ 49 $ 1,252 Provision/(Credit) (2 ) 9 3 10 Utilization and other (b) (145 ) (9 ) (15 ) (169 ) Balance, March 31, 2019 (c) $ 1,057 $ — $ 37 $ 1,093 (a) Included in Other current liabilities ( $823 million ) and Other noncurrent liabilities ( $428 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $669 million ) and Other noncurrent liabilities ( $424 million ).

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	3 Months Ended
	Mar. 31, 2019
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net The following table provides components of Other (income)/deductions––net : Three Months Ended (MILLIONS OF DOLLARS) March 31, April 1, Interest income (a) $ (66 ) $ (77 ) Interest expense (a) 361 310 Net interest expense 295 233 Royalty-related income (89 ) (96 ) Net gains on asset disposals (1 ) (7 ) Net gains recognized during the period on investments in equity securities (b) (111 ) (118 ) Net realized losses on sales of investments in debt securities — 3 Income from collaborations, out-licensing arrangements and sales of compound/product rights (c) (82 ) (142 ) Net periodic benefit credits other than service costs (d) (40 ) (82 ) Certain legal matters, net 4 (19 ) Certain asset impairments (e) 150 — Business and legal entity alignment costs (f) 119 3 Net losses on early retirement of debt (g) 138 3 Other, net (h) (291 ) 42 Other (income)/deductions––net $ 92 $ (178 ) (a) Interest income decreased in the first quarter of 2019 , primarily driven by a lower investment balance. Interest expense increased in the first quarter of 2019 , primarily as a result of higher interest rates. (b) The net gains on investments in equity securities for the first quarter of 2019 include gains of $43 million related to our investment in Allogene. The first quarter of 2018 included gains of $61 million related to our investment in ICU Medical stock. For additional information, see Note 7B . (c) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first quarter of 2019 , primarily includes $60 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® (fluticasone propionate and salmeterol inhalation powder). In the first quarter of 2018 , primarily includes, among other things, a $75 million milestone payment received from Shire related to their first dosing of a patient in a Phase III clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis, and a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. (d) For additional information, see Note 10 . (e) In the first quarter of 2019 , primarily includes intangible asset impairment charges of $130 million composed of: (i) $90 million related to WRDM IPR&D, which relates to a pre-clinical stage asset from our acquisition of Bamboo Therapeutics, Inc. (Bamboo) for gene therapies for the potential treatment of patients with certain rare diseases; and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products. The WRDM IPR&D intangible asset impairment charge was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development. The intangible asset impairment charge related to the Biopharma developed technology right reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first quarter of 2019 includes other asset impairments of $20 million . (f) In the first quarter of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In the first quarter of 2018, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (g) In first quarter of 2019 , represents net losses due to the early retirement of debt, inclusive of the related termination of cross-currency swaps. (h) In the first quarter of 2019 , includes among other things, credits of $72 million , reflecting the change in the fair value of contingent consideration, and dividend income of $64 million from our investment in ViiV. In the first quarter of 2018 , primarily includes, among other things, charges of $102 million , reflecting the change in the fair value of contingent consideration, partially offset by dividend income of $59 million from our investment in ViiV. The following table provides additional information about the intangible assets that were impaired in the first quarter of 2019 in Other (income)/deductions: Fair Value (a) Three Months Ended March 31, 2019 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– IPR&D (b) $ — $ — $ — $ — $ 90 Intangible assets––Developed technology right (b) — — — — 40 Total $ — $ — $ — $ — $ 130 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. (b) Reflects intangible assets written down to fair value in the first three months of 2019 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters

Tax Matters	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations Our effective tax rate for continuing operations was 10.0% for the first quarter of 2019 , compared to 13.5% for the first quarter of 2018 . The lower effective tax rate for the first quarter of 2019 in comparison with the same period in 2018 was primarily due to: • the tax benefit recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the enactment of the TCJA; • the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business, as well as • an increase in tax benefits associated with the resolution of certain tax positions pertaining to prior years, and the expiration of certain statutes of limitations. Our estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings for which we plan to elect, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 is reported in Income taxes payable ( $750 million ) and the remaining liability is reported in Other taxes payable in our consolidated balance sheet as of March 31, 2019. The first installment of $750 million was paid in April 2019. B. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2015 are currently under audit. Tax years 2016-2019 are open, but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2019), Japan (2017-2019), Europe (2011-2019, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2019, primarily reflecting Brazil) and Puerto Rico (2011-2019). C. Tax Provision on Other Comprehensive Income The following table provides the components of Tax provision on other comprehensive income : Three Months Ended (MILLIONS OF DOLLARS) March 31, April 1, Foreign currency translation adjustments, net (a) $ 27 $ (34 ) Unrealized holding gains/(losses) on derivative financial instruments, net 59 (4 ) Reclassification adjustments for (gains)/losses included in net income (55 ) (7 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — 1 4 (9 ) Unrealized holding gains on available-for-sale securities, net 5 20 Reclassification adjustments for (gains)/losses included in net income 1 (22 ) Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings (c) — (45 ) 7 (47 ) Benefit plans: actuarial gains, net — 38 Reclassification adjustments related to amortization 3 14 Reclassification adjustments related to settlements, net — 9 Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — 637 Other (5 ) (20 ) (2 ) 677 Reclassification adjustments related to amortization of prior service costs and other, net (11 ) (11 ) Reclassification adjustments related to curtailments of prior service costs and other, net — (7 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — (144 ) Other — 6 (11 ) (155 ) Tax provision on other comprehensive income $ 25 $ 432 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely. (b) For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report. (c) For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Note 1B . Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2018 $ (6,075 ) $ 167 $ (68 ) $ (6,027 ) $ 728 $ (11,275 ) Other comprehensive income/(loss) (a) 304 — 44 40 (35 ) 353 Balance, March 31, 2019 $ (5,772 ) $ 167 $ (24 ) $ (5,986 ) $ 693 $ (10,923 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $4 million loss for the first three months of 2019 . As of March 31, 2019 , with respect to derivative financial instruments, the amount of unrealized pre-tax net gains on derivative financial instruments estimated to be reclassified into income within the next 12 months is approximately $345 million . The net gains are expected to be offset primarily by net losses from reclassification adjustments related to foreign currency exchange-denominated forecasted intercompany inventory sales and available-for-sale debt securities.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2019
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments A. Fair Value Measurements Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in Pfizer’s 2018 Financial Report: March 31, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities: Money market funds $ 1,570 $ — $ 1,570 $ 1,571 $ — $ 1,571 Equity (a) 26 16 11 29 17 11 1,597 16 1,581 1,600 17 1,583 Classified as available-for-sale debt securities: Government and agency—non-U.S. 5,406 — 5,406 9,609 — 9,609 Corporate and other 1,773 — 1,773 5,482 — 5,482 7,180 — 7,180 15,091 — 15,091 Total short-term investments 8,776 16 8,760 16,691 17 16,674 Other current assets Derivative assets: Interest rate contracts 81 — 81 97 — 97 Foreign exchange contracts 482 — 482 477 — 477 Total other current assets 563 — 563 574 — 574 Long-term investments Classified as equity securities: Equity (a) 1,290 1,265 24 1,223 1,193 30 Classified as trading securities: Equity funds 52 51 — 50 50 — 1,341 1,317 24 1,273 1,243 30 Classified as available-for-sale debt securities: Government and agency—non-U.S. 44 — 44 94 — 94 Corporate and other 389 — 389 397 — 397 434 — 434 491 — 491 Total long-term investments 1,775 1,317 458 1,764 1,243 521 Other noncurrent assets Derivative assets: Interest rate contracts 461 — 461 335 — 335 Foreign exchange contracts 269 — 269 232 — 232 Total other noncurrent assets 731 — 731 566 — 566 Total assets $ 11,845 $ 1,333 $ 10,512 $ 19,595 $ 1,260 $ 18,335 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Interest rate contracts $ 2 $ — $ 2 $ 5 $ — $ 5 Foreign exchange contracts 89 — 89 78 — 78 Total other current liabilities 91 — 91 82 — 82 Other noncurrent liabilities Derivative liabilities: Interest rate contracts 178 — 178 378 — 378 Foreign exchange contracts 232 — 232 564 — 564 Total other noncurrent liabilities 410 — 410 942 — 942 Total liabilities $ 501 $ — $ 501 $ 1,024 $ — $ 1,024 (a) As of March 31, 2019 , short-term equity securities of $10 million and long-term equity securities of $23 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2018 , short-term equity securities of $11 million and long-term equity securities of $29 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: March 31, 2019 December 31, 2018 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 35,733 $ 39,016 $ 39,016 $ 32,909 $ 35,260 $ 35,260 The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of March 31, 2019 or December 31, 2018 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach. In addition, as of March 31, 2019 and December 31, 2018 , we had long-term receivables whose fair value is based on Level 3 inputs. As of March 31, 2019 and December 31, 2018 , the differences between the estimated fair values and carrying values of these receivables were not significant. Total Short-Term and Long-Term Investments The following table represents our investments by classification type: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Short-term investments Equity securities $ 1,597 $ 1,600 Available-for-sale debt securities 7,180 15,091 Held-to-maturity debt securities 906 1,003 Total Short-term investments $ 9,682 $ 17,694 Long-term investments Equity securities $ 1,290 $ 1,223 Trading equity funds securities 52 50 Available-for-sale debt securities 434 491 Held-to-maturity debt securities 55 59 Private equity investments at cost, as adjusted, or equity method 1,029 944 Total Long-term investments $ 2,859 $ 2,767 Held-to-maturity cash equivalents $ 213 $ 199 B. Investments At March 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at March 31, 2019 and December 31, 2018 is as follows, including, as of March 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: March 31, 2019 December 31, 2018 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 5,462 $ 6 $ (17 ) $ 5,451 $ 5,406 $ 44 $ — $ 5,451 $ 9,754 $ 7 $ (58 ) $ 9,703 Corporate and other (a) 2,178 1 (17 ) 2,162 1,773 386 3 2,162 5,905 — (27 ) 5,878 Held-to-maturity debt securities Time deposits and other 617 — — 617 562 16 39 617 668 — — 668 Government and agency –– non-U.S. 557 — — 557 557 — — 557 592 — — 592 Total debt securities $ 8,815 $ 7 $ (34 ) $ 8,787 $ 8,299 $ 446 $ 43 $ 8,787 $ 16,920 $ 8 $ (85 ) $ 16,842 (a) Primarily issued by a diverse group of corporations. The following table presents the net unrealized (gains) and losses for the period that relate to equity securities still held at the reporting date, calculated as follows: Three Months Ended (MILLIONS OF DOLLARS) March 31, 2019 April 1, 2018 Net gains recognized during the period on investments in equity securities (a) $ (111 ) $ (118 ) Less: Net gains recognized during the period on equity securities sold during the period (5 ) (19 ) Net unrealized gains during the reporting period on equity securities still held at the reporting date $ (106 ) $ (98 ) (a) The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 . C. Short-Term Borrowings Short-term borrowings include: (MILLIONS OF DOLLARS) March 31, December 31, Commercial paper $ 3,947 $ 3,100 Current portion of long-term debt, principal amount 4,473 4,781 Other short-term borrowings, principal amount (a) 1,000 966 Total short-term borrowings, principal amount 9,420 8,847 Net fair value adjustments related to hedging and purchase accounting (1 ) (5 ) Net unamortized discounts, premiums and debt issuance costs (9 ) (11 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 9,410 $ 8,831 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E . D. Long-Term Debt New Issuances In the first quarter of 2019, we issued the following senior unsecured notes: Principal (MILLIONS OF DOLLARS) Maturity Date As of March 31, 2019 2.800% notes (a) March 11, 2022 $ 500 2.950% notes (a) March 15, 2024 750 3.450% notes (a) March 15, 2029 1,750 3.900% notes (a) March 15, 2039 750 4.000% notes (a) March 15, 2049 1,250 Total long-term debt issued in the first quarter of 2019 (b) $ 5,000 (a) Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. (b) The weighted-average effective interest rate for the notes at issuance was 3.57% . Retirements In January 2019, we repurchased all €1.1 billion ( $1.3 billion , at exchange rates on settlement) principal amount outstanding of the 5.75% euro-denominated debt that was due June 2021 before the maturity date at a redemption value of €1.3 billion ( $1.5 billion , at exchange rates on settlement). As a result, in the first quarter of 2019, we recorded a net loss of approximately $138 million , which included the related termination of cross-currency swaps, and that was recorded in Other (income)/deductions––net in the condensed consolidated statement of income in the first quarter of 2019. For additional information, see Note 4 . The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) March 31, December 31, Total long-term debt, principal amount $ 35,122 $ 32,558 Net fair value adjustments related to hedging and purchase accounting 793 479 Net unamortized discounts, premiums and debt issuance costs (189 ) (136 ) Other long-term debt 7 7 Total long-term debt, carried at historical proceeds, as adjusted $ 35,733 $ 32,909 Current portion of long-term debt, carried at historical proceeds, as adjusted $ 4,471 $ 4,776 E. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions. The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen, U.K. pound, Chinese renminbi and Swedish krona . As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar -denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt. The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 18,353 $ 713 $ 248 $ 22,984 $ 654 $ 586 Interest rate contracts 11,145 543 180 11,145 432 383 1,255 429 1,085 968 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 15,111 38 72 $ 15,154 55 55 Total $ 1,294 $ 501 $ 1,140 $ 1,024 (a) As of March 31, 2019 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.5 billion . The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a) Amount of Gains/(Losses) (a), (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) Mar 31, Apr 1, Mar 31, Apr 1, Mar 31, Apr 1, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ 210 $ (143 ) $ 209 $ (72 ) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 56 28 54 27 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 329 (399 ) — — — — Hedged item (329 ) 399 — — — — Foreign exchange contracts — (7 ) — — — — Hedged item — 8 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 23 (5 ) — — The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness — — 41 2 24 6 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (d) — — 35 (42 ) — — Foreign currency long-term debt (d) — — 38 (92 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (120 ) (55 ) — — — — All other net — — 1 — — — $ (120 ) $ (55 ) $ 404 $ (251 ) $ 286 $ (39 ) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income–– Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net. (c) Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $202 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (d) Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.1 billion as of March 31, 2019 , which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $2.0 billion as of March 31, 2019 , which are used as hedging instruments in net investment hedges. The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended (MILLIONS OF DOLLARS) March 31, 2019 April 1, 2018 Cost of sales $ 2,433 $ 2,563 Other (income)/deductions—net 92 (178 ) The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: March 31, 2019 April 1, 2018 (MILLIONS OF DOLLARS) Carrying Amount of Hedged Assets/Liabilities Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets/Liabilities Carrying Amount of Hedged Assets/Liabilities Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets/Liabilities Short-term investments $ — $ — $ 286 $ (1 ) Long-term investments 45 (1 ) 45 (1 ) Short-term borrowings, including current portion of long-term debt 1,500 1 999 1 Long-term debt 9,945 (282) 11,372 100 Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties’ exposure to risk of defaulting on amounts owed by the other party. As of March 31, 2019 , the aggregate fair value of these derivative instruments that are in a net liability position was $209 million , for which we have posted collateral of $214 million in the normal course of business. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any additional collateral to our counterparties. As of March 31, 2019 , we received cash collateral of $948 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts that are in a net asset position. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt. F. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. For additional information on significant customers, see Notes to Consolidated Financial Statements–– Note 18C. Segment, Geographic and Other Revenue Information: Other Revenue Information in Pfizer’s 2018 Financial Report. As of March 31, 2019 , we had amounts due from a well-diversified, high quality group of banks ( $1.7 billion ) from around the world. For details about our investments, see Note 7B above . In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see Note 7E above.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : (MILLIONS OF DOLLARS) March 31, December 31, Finished goods $ 2,287 $ 2,262 Work-in-process 5,182 4,701 Raw materials and supplies 560 546 Inventories (a) $ 8,029 $ 7,508 Noncurrent inventories not included above (b) $ 637 $ 618 (a) The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery and market demand. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : March 31, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 89,379 $ (59,913 ) $ 29,465 $ 89,430 $ (58,895 ) $ 30,535 Brands 923 (717 ) 206 923 (708 ) 215 Licensing agreements and other 1,442 (1,150 ) 292 1,436 (1,140 ) 296 91,743 (61,780 ) 29,963 91,788 (60,743 ) 31,045 Indefinite-lived intangible assets Brands and other 1,994 1,994 1,994 1,994 IPR&D 2,082 2,082 2,171 2,171 4,076 4,076 4,165 4,165 Identifiable intangible assets (a) $ 95,819 $ (61,780 ) $ 34,039 $ 95,954 $ (60,743 ) $ 35,211 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization and intangible asset impairment charges, partially offset by additions for the period. See Note 4 for additional information on intangible asset impairments. Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: March 31, 2019 Biopharma Upjohn WRDM Developed technology rights 99 % 1 % — Brands, finite-lived 100 % — — Brands, indefinite-lived 42 % 58 % — IPR&D 87 % — 13 % Amortization Total amortization expense for finite-lived intangible assets was $1.2 billion for the first quarter of 2019 and $1.2 billion for the first quarter of 2018 . B. Goodwill Prior to 2019, we managed our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our 2019 fiscal year, we reorganized our commercial operations and our businesses are now managed through three different operating segments––Biopharma, Upjohn and Pfizer’s Consumer Healthcare business (see Note 13 for further information). Our Consumer Healthcare business is classified as held for sale as of December 31, 2018 and March 31, 2019 and, therefore the goodwill attributable to the Pfizer Consumer Healthcare business is included in Assets held for sale in the accompanying condensed consolidated balance sheets and not included in the table below (see Note 2 for further information). As a result of the reorganization of our commercial operations, our remaining goodwill is required to be reallocated amongst the new Biopharma and Upjohn operating segments. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new management structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year. The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) Biopharma Upjohn To be Allocated (a) Total Balance, December 31, 2018 $ — $ — $ 53,411 $ 53,411 Other (b) — — 76 76 Balance, March 31, 2019 $ — $ — $ 53,487 $ 53,487 (a) The amount to be allocated includes the goodwill associated with our former operating segments (see above), for which the allocation to our new reporting units, and, as a result, to the new operating segments, is pending. (b) Primarily reflects the impact of foreign exchange.

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	3 Months Ended
	Mar. 31, 2019
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The following table provides the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) March 31, 2019 April 1, 2018 March 31, 2019 April 1, 2018 March 31, 2019 April 1, 2018 March 31, 2019 April 1, 2018 Net periodic benefit cost/(credit): Service cost $ — $ — $ — $ — $ 32 $ 37 $ 9 $ 10 Interest cost 157 151 12 13 54 54 19 18 Expected return on plan assets (223 ) (263 ) — — (80 ) (92 ) (8 ) (9 ) Amortization of: Actuarial losses 37 30 2 4 20 26 1 2 Prior service credits (1 ) — — — (1 ) (1 ) (45 ) (45 ) Curtailments — 2 — — — — — (7 ) Settlements 1 20 — 17 — — — — Special termination benefits — — 6 — — — — — $ (28 ) $ (58 ) $ 20 $ 33 $ 25 $ 24 $ (23 ) $ (31 ) The following table provides the amounts we contributed, and the amounts we expect to contribute during 2019, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the three months ended March 31, 2019 $ 1 $ 71 $ 44 $ 29 Expected contributions from our general assets during 2019 (a) 10 167 191 149 (a) Contributions expected to be made for 2019 are inclusive of amounts contributed during the three months ended March 31, 2019. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Common Shareholders	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Common Shareholders	Earnings Per Common Share Attributable to Common Shareholders The following table provides the detailed calculation of EPS : Three Months Ended (IN MILLIONS) March 31, April 1, EPS Numerator––Basic Income from continuing operations $ 3,889 $ 3,571 Less: Net income attributable to noncontrolling interests 6 9 Income from continuing operations attributable to Pfizer Inc. 3,884 3,562 Less: Preferred stock dividends––net of tax — — Income from continuing operations attributable to Pfizer Inc. common shareholders 3,883 3,562 Discontinued operations––net of tax — (1 ) Net income attributable to Pfizer Inc. common shareholders $ 3,883 $ 3,560 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,884 $ 3,562 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — (1 ) Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,884 $ 3,561 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,635 5,957 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements 115 100 Weighted-average number of common shares outstanding––Diluted 5,750 6,057 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a) 2 2 Cash dividends declared per share $ 0.36 $ 0.34 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Commi

Contingencies and Certain Commitments	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Certain Commitments	Contingencies and Certain Commitments We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see Note 5B. For a discussion of our legal contingencies, see below. A. Legal Proceedings Our legal contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges. We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the United States. In June 2018, the Patent Trial and Appeal Board ruled on one patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision. Challenges to other patents remain pending in jurisdictions outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff Bosulif (bosutinib) In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Alembic is challenging a patent covering polymorphic forms of bosutinib, which expires in 2026, and a patent covering methods of treating chronic myelogenous leukemia, which expires in 2025. Sun is also challenging the same patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a patent-infringement action against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wyeth brought an additional patent-infringement action against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of two other patents challenged by Sun, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia, each of which expire in 2025. EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Precedex Premix In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer. In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In January 2018, the District Court ruled that one of the four patents was valid and infringed, and that the other three patents were invalid. In February and March 2018, respectively, each of Amneal and Hospira appealed the District Court decision to the U.S. Court of Appeals for the Federal Circuit. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that certain patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois, asserting the validity and infringement of those patents. In December 2018, the District Court ruled that the asserted patents were invalid. Hospira has appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira’s suit against Amneal (including all appeals). In December 2017, Gland Pharma Limited (Gland) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that six patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In February 2018, Hospira filed suit against Gland in the U.S. District Court for the District of Delaware asserting the validity and infringement of four patents that are the subject of the lawsuit. In December 2017, Jiangsu Hengrui Medicine Co., Ltd. (Hengrui) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that six patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In February 2018, Hospira filed suit against Hengrui in the U.S. District Court for the District of Delaware asserting the validity and infringement of four patents that are the subject of the lawsuit. In February 2018, Baxter Healthcare Corporation (Baxter) filed a declaratory judgment action against Hospira in the U.S. District Court for the District of Delaware seeking a declaration of non-infringement of four patents relating to the Precedex premix formulations and their use. One of the patents included in the action expires in 2019 and the other three patents expire in 2032. In March 2018, Hospira filed a counterclaim for infringement of the patent expiring in 2019. In November 2018, the case was dismissed by mutual agreement of the parties. Xeljanz (tofacitinib) In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In November 2018, we settled all of our claims against MicroLabs on terms not material to Pfizer. Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another patent challenged by Sun Pharmaceutical Industries Ltd, which covers the active ingredient and expires in December 2025. In October 2018, we brought a third patent infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering the extended release formulation of tofacitinib, which expires in 2034. In March and April 2019, the actions against Sun Pharmaceutical Industries Ltd. were dismissed by mutual agreement of the parties. In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Also, in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively, Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. (collectively, Breckenridge) on the two patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of four additional patents challenged by Breckenridge, three of which expire in December 2020 and one of which expires in December 2025. In March 2018, we brought another patent infringement action against Prinston in the U.S. District Court for the District of Delaware asserting the infringement and validity of an additional patent, which had been subsequently challenged by Prinston and which expires in December 2025. In May 2018, we settled all of our claims against Breckenridge on terms not material to Pfizer. In January 2019, we settled all of our claims against Prinston on terms not material to Pfizer. In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In March 2019, we brought a separate patent infringement action against Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, Ajanta) in the U.S. District Court for the District of Delaware asserting the infringement and validity of two patents: the patent covering the active ingredient that expires in December 2025 and the patent covering a polymorphic form of tofacitinib that expires in 2023, each of which Ajanta challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Inlyta (axitinib) In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. Kerydin (tavaborole) In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary , filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia. Ibrance (palbociclib) In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of two composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. Matters Involving Our Collaboration/Licensing Partners Xtandi (enzalutamide) In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies’ respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane Laboratories Inc. (Roxane) in the same court in connection with Roxane’s abbreviated new drug application with the FDA for approval to market a generic version of enzalutamide. In June and July 2018, we settled all of our claims against Actavis and Apotex, respectively, on terms not material to Pfizer. Eliquis In February, March, and April 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. We and BMS have settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future. Actions In Which We Are The Defendant Inflectra (infliximab-dyyb) In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents relating to infliximab, its manufacture and use. Claims with respect to four of the patents were dismissed by the plaintiffs, leaving two patents at issue: the infliximab antibody patent and a patent relating to cell culture media. In January 2018, the antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, the U.S. District Court for the District of Massachusetts granted defendants’ motion for summary judgment and ruled that the patent relating to cell culture media was not infringed. Janssen appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of March 31, 2019 , approximately 46,400 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Lipitor • Antitrust Actions Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. • Personal Injury Actions A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502 ) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and Pfizer’s Consumer Healthcare business (Consumer Healthcare). The Biopharma, Upjohn and Consumer Healthcare segments are each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn and Consumer Healthcare are responsible for their own R&D activities while Biopharma receives its R&D services from GPD and WRDM. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the three operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. As our operations were not managed under the new structure until the beginning of fiscal 2019, certain costs and expenses could not be directly attributed to one of the new operating segments. As a result, our operating segment results for the first quarter of 2018 include allocations, which management believes are reasonable. Operating Segments Some additional information about our Biopharma and Upjohn business segments follows: Biopharma is a science-based innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The new Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer’s contract manufacturing operation, Pfizer CentreOne. We also incorporated our biosimilar portfolio into our Oncology and Inflammation & Immunology business units and certain legacy established products into the Internal Medicine business unit. Each business unit is committed to improving health with our innovative products from prevention to treatment to wellness – at every stage of life in communities across the globe. Upjohn is a global, primarily off-patent branded and generic established medicines business, which includes 20 primarily off-patent solid oral dose legacy brands, as well as certain generic medicines. Select products include: - Prevnar 13/Prevenar 13 - Eliquis - Enbrel (outside the U.S. and Canada) Xeljanz - Chantix/Champix - Sutent Select products include: - Lyrica - Celebrex - Viagra - Certain generic medicines Pfizer’s Consumer Healthcare segment is an over-the-counter medicines business, which we announced on December 19, 2018 will be contributed to, and combined with, GSK’s consumer healthcare business to form a new consumer healthcare joint venture. See Note 2 for additional information. Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following: • WRDM––the R&D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payers and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines. • GPD––the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies. • Other––the operating results of our Consumer Healthcare business, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization. • Corporate and Other Unallocated––the costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as restructuring charges, legal charges or net gains and losses on investments in equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $155 billion as of March 31, 2019 and $159 billion as of December 31, 2018 . Selected Income Statement Information The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) March 31, April 1, March 31, April 1, Reportable Segments: Biopharma $ 9,185 $ 8,881 $ 5,888 $ 5,823 Upjohn 3,075 3,120 2,274 2,168 Total reportable segments 12,259 12,001 8,162 7,991 Other business activities — — (1,113 ) (1,187 ) Reconciling Items: Corporate and other unallocated 858 905 (1,278 ) (1,325 ) Purchase accounting adjustments — — (1,038 ) (1,221 ) Acquisition-related costs — — (28 ) (48 ) Certain significant items (b) — — (382 ) (83 ) $ 13,118 $ 12,906 $ 4,323 $ 4,127 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $64 million in the first quarter of 2019 and $59 million in the first quarter of 2018 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the first quarter of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction ini tiatives that are not associated with an acquisition of $57 million , (ii) income for certain legal matters of $6 million , (iii) certain asset impairment charges of $139 million , (iv) charges for business and legal entity alignment of $119 million , (v) net gains recognized during the period on investments in equity securities of $111 million , (vi) net losses on early retirement of debt of $138 million and (vii) other charges of $46 million . For additional information, see Note 3 and Note 4. For Earnings in the first quarter of 2018 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $51 million , (ii) income for certain legal matters of $19 million , (iii) charges for business and legal entity alignment of $3 million , (iv) net gains recognized during the period on investments in equity securities of $118 million , (v) net losses on early retirement of debt of $3 million and (vi) other charges of $162 million , which includes, among other things, a $108 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA. For additional information, see Note 3 and Note 4 . Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information The following table provides revenues by geographic area: Three Months Ended (MILLIONS OF DOLLARS) March 31, April 1, % Change U.S. $ 6,175 $ 6,275 (2 ) Developed Europe (a) 2,086 2,092 — Developed Rest of World (b) 1,535 1,461 5 Emerging Markets (c) 3,322 3,078 8 Revenues $ 13,118 $ 12,906 2 (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the first quarter of 2019 and 2018 . (b) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey. C. Other Revenue Information Significant Product Revenues The following table provides detailed revenue information: (MILLIONS OF DOLLARS) Three Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS March 31, April 1, TOTAL REVENUES $ 13,118 $ 12,906 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) (a) $ 9,185 $ 8,881 Internal Medicine (b) $ 2,217 $ 2,071 Eliquis alliance revenues and direct sales Atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,011 765 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 273 251 Premarin family Symptoms of menopause 168 191 BMP2 Development of bone and cartilage 67 73 Toviaz Overactive bladder 60 60 All other Internal Medicine Various 639 730 Oncology (c) $ 1,961 $ 1,760 Ibrance Advanced breast cancer 1,133 933 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 232 262 Xtandi alliance revenues Castration-resistant prostate cancer 168 159 Xalkori ALK-positive and ROS1-positive advanced NSCLC 123 153 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 80 60 Inlyta Advanced RCC 73 74 All other Oncology Various 153 119 Hospital (d) $ 1,887 $ 2,026 Sulperazon Treatment of infections 177 168 Medrol (e) Steroid anti-inflammatory 120 136 Zithromax (e) Bacterial infections 104 101 Vfend (e) Fungal infections 85 98 EpiPen Epinephrine injection used in treatment of life-threatening allergic reactions 66 52 Zyvox (e) Bacterial infections 64 68 Fragmin Slows blood clotting 60 70 Zosyn/Tazocin Antibiotic 51 61 Pfizer CentreOne (f) Various 176 171 All other Anti-infectives Various 354 392 All other Hospital (d) Various 631 708 Vaccines $ 1,612 $ 1,463 Prevnar 13/Prevenar 13 Vaccines for prevention of pneumococcal disease 1,486 1,380 All other Vaccines Various 126 83 Inflammation & Immunology (I&I) (g) $ 1,037 $ 1,013 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 451 506 Xeljanz RA, PsA, UC 423 326 Inflectra/Remsima Inflammatory diseases 138 145 Eucrisa Mild-to-moderate atopic dermatitis (eczema) 22 26 All other I&I Various 3 11 Rare Disease $ 470 $ 549 BeneFIX Hemophilia 125 147 Genotropin Replacement of human growth hormone 107 132 Refacto AF/Xyntha Hemophilia 106 130 Somavert Acromegaly 59 63 All other Rare Disease Various 72 76 (MILLIONS OF DOLLARS) Three Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS March 31, April 1, UPJOHN (b) , (h) $ 3,075 $ 3,120 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 1,186 1,213 Lipitor Reduction of LDL cholesterol 622 511 Norvasc Hypertension 300 256 Celebrex Arthritis pain and inflammation, acute pain 174 145 Viagra Erectile dysfunction 145 187 Effexor Depression and certain anxiety disorders 77 71 Zoloft Depression and certain anxiety disorders 69 74 Xalatan/Xalacom Glaucoma and ocular hypertension 62 72 All other Upjohn Various 440 591 CONSUMER HEALTHCARE BUSINESS (i) $ 858 $ 905 Total Alliance revenues Various $ 1,090 $ 855 (a) The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Hospital. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne (f) . (b) We reclassified certain products from the Legacy Established Products (LEP) category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 product revenues to the current presentation. (c) We performed certain reclassifications in the All other Oncology category to conform 2018 product revenues to the current presentation. (d) Hospital is a new business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy Sterile Injectables Pharmaceuticals (SIP) category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 product revenues to the current presentation. Hospital also includes Pfizer CentreOne (f) . All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (e) 2018 revenues for Medrol, Zithromax, Vfend and Zyvox may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category. (f) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne. (g) We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2018 product revenues to the current presentation. (h) Pfizer’s Upjohn business encompasses primarily off-patent branded and generic established medicines that includes 20 of our primarily off-patent solid oral dose legacy brands including Lyrica, Lipitor, Norvasc, Celebrex and Viagra, as well as certain generic medicines. (i) Pfizer’s Consumer Healthcare business is an over-the-counter medicines business, which we announced in December 2018 will be contributed to, and combined with, GSK’s consumer healthcare business to form a new consumer healthcare joint venture, of which we will own 32% , subject to customary closing conditions, including GSK shareholder approval, which occurred on May 8, 2019, and required regulatory approvals.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three months ended February 24, 2019 and February 25, 2018 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three months ended March 31, 2019 and April 1, 2018 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2018 Financial Report. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13 . Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Adoption of New Accounting Standards	Adoption of New Accounting Standards On January 1, 2019, we adopted four new accounting standards. Leases ––On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of $1.4 billion and current and noncurrent operating lease liabilities of $1.4 billion as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $30 million on a pre-tax basis ( $20 million after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules. Adopting the standard related to leases impacted our prior period condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2018 Effect of Change Higher/(Lower) Balance at January 1, 2019 Other current assets $ 2,461 $ (1 ) $ 2,460 Noncurrent deferred tax assets and other noncurrent tax assets 1,924 (11 ) 1,913 Other noncurrent assets 2,799 1,351 4,149 Other current liabilities 10,753 258 11,011 Other noncurrent liabilities 5,850 1,060 6,910 Retained earnings 89,554 20 89,574 Adoption of the standard related to leases did not have a material impact on our condensed consolidated statements of income or condensed consolidated statements of cash flows for the quarter ended March 31, 2019 . For additional information, see Note 1D . Amortization Period for Certain Callable Debt Securities Held at a Premium ––We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features ––We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Share-Based Payments to Nonemployees ––We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. On January 1, 2018, we adopted eleven new accounting standards. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 included in our 2018 Financial Report. C. Revenues and Trade Accounts Receivable Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.5 billion as of March 31, 2019 and $5.4 billion as of December 31, 2018 . The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,232 $ 1,288 Other current liabilities : Accrued rebates 3,344 3,208 Other accruals 559 531 Other noncurrent liabilities 410 399 Total accrued rebates and other accruals $ 5,544 $ 5,426 D. Leases On January 1, 2019, we adopted a new accounting standard for leases. For further information, see Note 1B . We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $59 million for the three months ended March 31, 2019 . We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes. We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. For operating leases, the ROU assets and liabilities are presented in our condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) Balance Sheet Classification Balance at March 31, 2019 ROU assets Other noncurrent assets $ 1,280 Lease liabilities (short-term) Other current liabilities 253 Lease liabilities (long-term) Other noncurrent liabilities 1,043 Our total lease costs are as follows: Three Months Ended (MILLIONS OF DOLLARS) March 31, 2019 Operating lease cost $ 100 Variable lease cost 59 Sublease income (10 ) Total lease cost $ 149 Other supplemental information includes the following: (MILLIONS OF DOLLARS) Weighted-Average Remaining Contractual Lease Term (Years) Three Months Ended March 31, 2019 Operating leases 7.5 Weighted-average discount rate: Operating leases 3.7 % Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 78 ROU assets obtained in exchange for new operating lease liabilities 46 The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of March 31, 2019: (MILLIONS OF DOLLARS) Period Operating Lease Liabilities Next one year (a) $ 287 1-2 years 241 2-3 years 207 3-4 years 175 4-5 years 144 Thereafter 435 Total undiscounted lease payments 1,489 Less: Imputed interest 193 Present Value of Minimum Lease Payments 1,296 Less: Current portion 253 Noncurrent portion $ 1,043 (a) Reflects lease payments due within 12 months subsequent to the balance sheet date. In April 2018, we entered an agreement to lease space in an office building in New York City. We will relocate our global headquarters to this property with commencement expected in 2022. Our future minimum rental commitment under this 20 -year lease is approximately $1.7 billion . Prior to our adoption of the new lease standard, rental expense, net of sublease income, was $301 million in 2018, $314 million in 2017 and $292 million in 2016. As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2019 2020 2021 2022 2023 After 2023 Lease commitments $ 300 $ 252 $ 210 $ 267 $ 248 $ 2,040

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Impact of Adoption of Accounting Standard Updates	Adopting the standard related to leases impacted our prior period condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2018 Effect of Change Higher/(Lower) Balance at January 1, 2019 Other current assets $ 2,461 $ (1 ) $ 2,460 Noncurrent deferred tax assets and other noncurrent tax assets 1,924 (11 ) 1,913 Other noncurrent assets 2,799 1,351 4,149 Other current liabilities 10,753 258 11,011 Other noncurrent liabilities 5,850 1,060 6,910 Retained earnings 89,554 20 89,574
Schedule of Balance Sheet Classification of Accruals	The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,232 $ 1,288 Other current liabilities : Accrued rebates 3,344 3,208 Other accruals 559 531 Other noncurrent liabilities 410 399 Total accrued rebates and other accruals $ 5,544 $ 5,426
ROU Assets and Liabilities Presented in Condensed Consolidated Balance Sheets	For operating leases, the ROU assets and liabilities are presented in our condensed consolidated balance sheet as follows: (MILLIONS OF DOLLARS) Balance Sheet Classification Balance at March 31, 2019 ROU assets Other noncurrent assets $ 1,280 Lease liabilities (short-term) Other current liabilities 253 Lease liabilities (long-term) Other noncurrent liabilities 1,043
Total Lease Costs and Other Supplemental Information	Our total lease costs are as follows: Three Months Ended (MILLIONS OF DOLLARS) March 31, 2019 Operating lease cost $ 100 Variable lease cost 59 Sublease income (10 ) Total lease cost $ 149 Other supplemental information includes the following: (MILLIONS OF DOLLARS) Weighted-Average Remaining Contractual Lease Term (Years) Three Months Ended March 31, 2019 Operating leases 7.5 Weighted-average discount rate: Operating leases 3.7 % Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 78 ROU assets obtained in exchange for new operating lease liabilities 46
Schedule of Future Minimum Rental Payments for Operating Leases	The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the condensed consolidated balance sheet as of March 31, 2019: (MILLIONS OF DOLLARS) Period Operating Lease Liabilities Next one year (a) $ 287 1-2 years 241 2-3 years 207 3-4 years 175 4-5 years 144 Thereafter 435 Total undiscounted lease payments 1,489 Less: Imputed interest 193 Present Value of Minimum Lease Payments 1,296 Less: Current portion 253 Noncurrent portion $ 1,043 (a) Reflects lease payments due within 12 months subsequent to the balance sheet date.
Schedule of Future Minimum Rental Payments for Operating Leases	As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2019 2020 2021 2022 2023 After 2023 Lease commitments $ 300 $ 252 $ 210 $ 267 $ 248 $ 2,040

Assets and Liabilities Held f_2

Assets and Liabilities Held for Sale Assets and Liabilities Held for Sale (Tables)	3 Months Ended
	Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Amounts Associated with the Consumer Healthcare Business	The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Assets Held for Sale Cash and cash equivalents $ 61 $ 32 Trade accounts receivable, less allowance for doubtful accounts 550 532 Inventories 563 538 Other current assets 57 56 PP&E 687 675 Identifiable intangible assets, less accumulated amortization 5,776 5,763 Goodwill 1,972 1,972 Noncurrent deferred tax assets and other noncurrent tax assets 59 54 Other noncurrent assets 105 57 Total Consumer Healthcare assets held for sale 9,830 9,678 Other assets held for sale (a) 47 46 Assets held for sale $ 9,877 $ 9,725 Liabilities Held for Sale Trade accounts payable $ 335 $ 406 Income taxes payable 55 39 Accrued compensation and related items 140 93 Other current liabilities 371 353 Pension benefit obligations, net 39 39 Postretirement benefit obligations, net 33 33 Noncurrent deferred tax liabilities 884 870 Other noncurrent liabilities 78 56 Total Consumer Healthcare liabilities held for sale $ 1,935 $ 1,890 (a) Other assets held for sale consist of PP&E.

Restructuring Charges and Oth_2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	3 Months Ended
	Mar. 31, 2019
Restructuring and Related Activities [Abstract]
Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended (MILLIONS OF DOLLARS) March 31, April 1, Restructuring charges/(credits): Employee terminations $ (2 ) $ (8 ) Asset impairments 9 2 Exit costs 3 (3 ) Restructuring charges/(credits) (a) 10 (9 ) Integration costs (b) 36 52 Restructuring charges and certain acquisition-related costs 46 43 Net periodic benefit costs recorded in Other (income)/deductions––net 6 32 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (c) : Cost of sales 9 17 Selling, informational and administrative expenses 1 — Research and development expenses 3 — Total additional depreciation––asset restructuring 13 17 Implementation costs recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 13 16 Selling, informational and administrative expenses 9 17 Research and development expenses 4 6 Total implementation costs 26 39 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 92 $ 131 (a) In the first quarter of 2019 , restructuring charges are primarily associated with cost reduction initiatives and mainly represent asset write downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. In the three months ended April 1, 2018 , restructuring credits were primarily due to the reversal of previously recorded accruals for exit costs related to our acquisition of Hospira, as well as cost-reduction and productivity initiatives not associated with acquisitions. The restructuring activities for the three months ended March 31, 2019 are associated with the following: • Biopharma ( $13 million charge ); Upjohn ( $13 million credit ); and Other ( $10 million charge). The restructuring activities for the three months ended April 1, 2018 are associated with the following: • Total reportable segments ( $14 million credit); and Other ( $4 million charge). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments. (b) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the first quarter of 2019 and 2018, integration costs were primarily related to our acquisition of Hospira. (c) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (d) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components of and Changes in Restructuring Accruals	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2018 (a) $ 1,203 $ — $ 49 $ 1,252 Provision/(Credit) (2 ) 9 3 10 Utilization and other (b) (145 ) (9 ) (15 ) (169 ) Balance, March 31, 2019 (c) $ 1,057 $ — $ 37 $ 1,093 (a) Included in Other current liabilities ( $823 million ) and Other noncurrent liabilities ( $428 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $669 million ) and Other noncurrent liabilities ( $424 million ).

Other (Income)_Deductions - N_2

Other (Income)/Deductions - Net (Tables)	3 Months Ended
	Mar. 31, 2019
Other Income and Expenses [Abstract]
Schedule of Other (Income)/Deductions - Net	The following table provides components of Other (income)/deductions––net : Three Months Ended (MILLIONS OF DOLLARS) March 31, April 1, Interest income (a) $ (66 ) $ (77 ) Interest expense (a) 361 310 Net interest expense 295 233 Royalty-related income (89 ) (96 ) Net gains on asset disposals (1 ) (7 ) Net gains recognized during the period on investments in equity securities (b) (111 ) (118 ) Net realized losses on sales of investments in debt securities — 3 Income from collaborations, out-licensing arrangements and sales of compound/product rights (c) (82 ) (142 ) Net periodic benefit credits other than service costs (d) (40 ) (82 ) Certain legal matters, net 4 (19 ) Certain asset impairments (e) 150 — Business and legal entity alignment costs (f) 119 3 Net losses on early retirement of debt (g) 138 3 Other, net (h) (291 ) 42 Other (income)/deductions––net $ 92 $ (178 ) (a) Interest income decreased in the first quarter of 2019 , primarily driven by a lower investment balance. Interest expense increased in the first quarter of 2019 , primarily as a result of higher interest rates. (b) The net gains on investments in equity securities for the first quarter of 2019 include gains of $43 million related to our investment in Allogene. The first quarter of 2018 included gains of $61 million related to our investment in ICU Medical stock. For additional information, see Note 7B . (c) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first quarter of 2019 , primarily includes $60 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® (fluticasone propionate and salmeterol inhalation powder). In the first quarter of 2018 , primarily includes, among other things, a $75 million milestone payment received from Shire related to their first dosing of a patient in a Phase III clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis, and a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. (d) For additional information, see Note 10 . (e) In the first quarter of 2019 , primarily includes intangible asset impairment charges of $130 million composed of: (i) $90 million related to WRDM IPR&D, which relates to a pre-clinical stage asset from our acquisition of Bamboo Therapeutics, Inc. (Bamboo) for gene therapies for the potential treatment of patients with certain rare diseases; and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products. The WRDM IPR&D intangible asset impairment charge was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development. The intangible asset impairment charge related to the Biopharma developed technology right reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first quarter of 2019 includes other asset impairments of $20 million . (f) In the first quarter of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In the first quarter of 2018, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (g) In first quarter of 2019 , represents net losses due to the early retirement of debt, inclusive of the related termination of cross-currency swaps. (h) In the first quarter of 2019 , includes among other things, credits of $72 million , reflecting the change in the fair value of contingent consideration, and dividend income of $64 million from our investment in ViiV. In the first quarter of 2018 , primarily includes, among other things, charges of $102 million , reflecting the change in the fair value of contingent consideration, partially offset by dividend income of $59 million from our investment in ViiV. The following table provides additional information about the intangible assets that were impaired in the first quarter of 2019 in Other (income)/deductions: Fair Value (a) Three Months Ended March 31, 2019 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– IPR&D (b) $ — $ — $ — $ — $ 90 Intangible assets––Developed technology right (b) — — — — 40 Total $ — $ — $ — $ — $ 130
Schedule of Additional Information About Intangible Assets Impaired	The following table provides additional information about the intangible assets that were impaired in the first quarter of 2019 in Other (income)/deductions: Fair Value (a) Three Months Ended March 31, 2019 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– IPR&D (b) $ — $ — $ — $ — $ 90 Intangible assets––Developed technology right (b) — — — — 40 Total $ — $ — $ — $ — $ 130 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. (b) Reflects intangible assets written down to fair value in the first three months of 2019 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters (Tables)

Tax Matters (Tables)	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Tax Provision (Benefit) on Other Comprehensive Income/(Loss)	The following table provides the components of Tax provision on other comprehensive income : Three Months Ended (MILLIONS OF DOLLARS) March 31, April 1, Foreign currency translation adjustments, net (a) $ 27 $ (34 ) Unrealized holding gains/(losses) on derivative financial instruments, net 59 (4 ) Reclassification adjustments for (gains)/losses included in net income (55 ) (7 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — 1 4 (9 ) Unrealized holding gains on available-for-sale securities, net 5 20 Reclassification adjustments for (gains)/losses included in net income 1 (22 ) Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings (c) — (45 ) 7 (47 ) Benefit plans: actuarial gains, net — 38 Reclassification adjustments related to amortization 3 14 Reclassification adjustments related to settlements, net — 9 Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — 637 Other (5 ) (20 ) (2 ) 677 Reclassification adjustments related to amortization of prior service costs and other, net (11 ) (11 ) Reclassification adjustments related to curtailments of prior service costs and other, net — (7 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — (144 ) Other — 6 (11 ) (155 ) Tax provision on other comprehensive income $ 25 $ 432 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely. (b) For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report. (c) For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Note 1B . Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2018 $ (6,075 ) $ 167 $ (68 ) $ (6,027 ) $ 728 $ (11,275 ) Other comprehensive income/(loss) (a) 304 — 44 40 (35 ) 353 Balance, March 31, 2019 $ (5,772 ) $ 167 $ (24 ) $ (5,986 ) $ 693 $ (10,923 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $4 million loss for the first three months of 2019 .

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Financial Instruments [Abstract]
Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis	The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in Pfizer’s 2018 Financial Report: March 31, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities: Money market funds $ 1,570 $ — $ 1,570 $ 1,571 $ — $ 1,571 Equity (a) 26 16 11 29 17 11 1,597 16 1,581 1,600 17 1,583 Classified as available-for-sale debt securities: Government and agency—non-U.S. 5,406 — 5,406 9,609 — 9,609 Corporate and other 1,773 — 1,773 5,482 — 5,482 7,180 — 7,180 15,091 — 15,091 Total short-term investments 8,776 16 8,760 16,691 17 16,674 Other current assets Derivative assets: Interest rate contracts 81 — 81 97 — 97 Foreign exchange contracts 482 — 482 477 — 477 Total other current assets 563 — 563 574 — 574 Long-term investments Classified as equity securities: Equity (a) 1,290 1,265 24 1,223 1,193 30 Classified as trading securities: Equity funds 52 51 — 50 50 — 1,341 1,317 24 1,273 1,243 30 Classified as available-for-sale debt securities: Government and agency—non-U.S. 44 — 44 94 — 94 Corporate and other 389 — 389 397 — 397 434 — 434 491 — 491 Total long-term investments 1,775 1,317 458 1,764 1,243 521 Other noncurrent assets Derivative assets: Interest rate contracts 461 — 461 335 — 335 Foreign exchange contracts 269 — 269 232 — 232 Total other noncurrent assets 731 — 731 566 — 566 Total assets $ 11,845 $ 1,333 $ 10,512 $ 19,595 $ 1,260 $ 18,335 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Interest rate contracts $ 2 $ — $ 2 $ 5 $ — $ 5 Foreign exchange contracts 89 — 89 78 — 78 Total other current liabilities 91 — 91 82 — 82 Other noncurrent liabilities Derivative liabilities: Interest rate contracts 178 — 178 378 — 378 Foreign exchange contracts 232 — 232 564 — 564 Total other noncurrent liabilities 410 — 410 942 — 942 Total liabilities $ 501 $ — $ 501 $ 1,024 $ — $ 1,024 (a) As of March 31, 2019 , short-term equity securities of $10 million and long-term equity securities of $23 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2018 , short-term equity securities of $11 million and long-term equity securities of $29 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis	The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: March 31, 2019 December 31, 2018 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 35,733 $ 39,016 $ 39,016 $ 32,909 $ 35,260 $ 35,260
Investments by Classification Type	The following table represents our investments by classification type: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Short-term investments Equity securities $ 1,597 $ 1,600 Available-for-sale debt securities 7,180 15,091 Held-to-maturity debt securities 906 1,003 Total Short-term investments $ 9,682 $ 17,694 Long-term investments Equity securities $ 1,290 $ 1,223 Trading equity funds securities 52 50 Available-for-sale debt securities 434 491 Held-to-maturity debt securities 55 59 Private equity investments at cost, as adjusted, or equity method 1,029 944 Total Long-term investments $ 2,859 $ 2,767 Held-to-maturity cash equivalents $ 213 $ 199
Schedule of Held-to-maturity Securities	At March 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at March 31, 2019 and December 31, 2018 is as follows, including, as of March 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: March 31, 2019 December 31, 2018 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 5,462 $ 6 $ (17 ) $ 5,451 $ 5,406 $ 44 $ — $ 5,451 $ 9,754 $ 7 $ (58 ) $ 9,703 Corporate and other (a) 2,178 1 (17 ) 2,162 1,773 386 3 2,162 5,905 — (27 ) 5,878 Held-to-maturity debt securities Time deposits and other 617 — — 617 562 16 39 617 668 — — 668 Government and agency –– non-U.S. 557 — — 557 557 — — 557 592 — — 592 Total debt securities $ 8,815 $ 7 $ (34 ) $ 8,787 $ 8,299 $ 446 $ 43 $ 8,787 $ 16,920 $ 8 $ (85 ) $ 16,842 (a) Primarily issued by a diverse group of corporations.
Schedule of Available-for-sale Securities	At March 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at March 31, 2019 and December 31, 2018 is as follows, including, as of March 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: March 31, 2019 December 31, 2018 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 5,462 $ 6 $ (17 ) $ 5,451 $ 5,406 $ 44 $ — $ 5,451 $ 9,754 $ 7 $ (58 ) $ 9,703 Corporate and other (a) 2,178 1 (17 ) 2,162 1,773 386 3 2,162 5,905 — (27 ) 5,878 Held-to-maturity debt securities Time deposits and other 617 — — 617 562 16 39 617 668 — — 668 Government and agency –– non-U.S. 557 — — 557 557 — — 557 592 — — 592 Total debt securities $ 8,815 $ 7 $ (34 ) $ 8,787 $ 8,299 $ 446 $ 43 $ 8,787 $ 16,920 $ 8 $ (85 ) $ 16,842 (a) Primarily issued by a diverse group of corporations.
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	At March 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at March 31, 2019 and December 31, 2018 is as follows, including, as of March 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: March 31, 2019 December 31, 2018 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 5,462 $ 6 $ (17 ) $ 5,451 $ 5,406 $ 44 $ — $ 5,451 $ 9,754 $ 7 $ (58 ) $ 9,703 Corporate and other (a) 2,178 1 (17 ) 2,162 1,773 386 3 2,162 5,905 — (27 ) 5,878 Held-to-maturity debt securities Time deposits and other 617 — — 617 562 16 39 617 668 — — 668 Government and agency –– non-U.S. 557 — — 557 557 — — 557 592 — — 592 Total debt securities $ 8,815 $ 7 $ (34 ) $ 8,787 $ 8,299 $ 446 $ 43 $ 8,787 $ 16,920 $ 8 $ (85 ) $ 16,842 (a) Primarily issued by a diverse group of corporations.
Schedule of Gains and Losses on Investment Securities	The following table presents the net unrealized (gains) and losses for the period that relate to equity securities still held at the reporting date, calculated as follows: Three Months Ended (MILLIONS OF DOLLARS) March 31, 2019 April 1, 2018 Net gains recognized during the period on investments in equity securities (a) $ (111 ) $ (118 ) Less: Net gains recognized during the period on equity securities sold during the period (5 ) (19 ) Net unrealized gains during the reporting period on equity securities still held at the reporting date $ (106 ) $ (98 ) (a) The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
Schedule of Short-term Borrowings	Short-term borrowings include: (MILLIONS OF DOLLARS) March 31, December 31, Commercial paper $ 3,947 $ 3,100 Current portion of long-term debt, principal amount 4,473 4,781 Other short-term borrowings, principal amount (a) 1,000 966 Total short-term borrowings, principal amount 9,420 8,847 Net fair value adjustments related to hedging and purchase accounting (1 ) (5 ) Net unamortized discounts, premiums and debt issuance costs (9 ) (11 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 9,410 $ 8,831 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E .
Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments	The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) March 31, December 31, Total long-term debt, principal amount $ 35,122 $ 32,558 Net fair value adjustments related to hedging and purchase accounting 793 479 Net unamortized discounts, premiums and debt issuance costs (189 ) (136 ) Other long-term debt 7 7 Total long-term debt, carried at historical proceeds, as adjusted $ 35,733 $ 32,909 Current portion of long-term debt, carried at historical proceeds, as adjusted $ 4,471 $ 4,776 In the first quarter of 2019, we issued the following senior unsecured notes: Principal (MILLIONS OF DOLLARS) Maturity Date As of March 31, 2019 2.800% notes (a) March 11, 2022 $ 500 2.950% notes (a) March 15, 2024 750 3.450% notes (a) March 15, 2029 1,750 3.900% notes (a) March 15, 2039 750 4.000% notes (a) March 15, 2049 1,250 Total long-term debt issued in the first quarter of 2019 (b) $ 5,000 (a) Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest. (b) The weighted-average effective interest rate for the notes at issuance was 3.57% .
Schedule of Derivative Instruments	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 18,353 $ 713 $ 248 $ 22,984 $ 654 $ 586 Interest rate contracts 11,145 543 180 11,145 432 383 1,255 429 1,085 968 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 15,111 38 72 $ 15,154 55 55 Total $ 1,294 $ 501 $ 1,140 $ 1,024 (a) As of March 31, 2019 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.5 billion .
Schedule of Derivative Assets	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 18,353 $ 713 $ 248 $ 22,984 $ 654 $ 586 Interest rate contracts 11,145 543 180 11,145 432 383 1,255 429 1,085 968 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 15,111 38 72 $ 15,154 55 55 Total $ 1,294 $ 501 $ 1,140 $ 1,024 (a) As of March 31, 2019 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.5 billion .
Schedule of Derivative Liabilities	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) March 31, 2019 December 31, 2018 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 18,353 $ 713 $ 248 $ 22,984 $ 654 $ 586 Interest rate contracts 11,145 543 180 11,145 432 383 1,255 429 1,085 968 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 15,111 38 72 $ 15,154 55 55 Total $ 1,294 $ 501 $ 1,140 $ 1,024 (a) As of March 31, 2019 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.5 billion .
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a) Amount of Gains/(Losses) (a), (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) Mar 31, Apr 1, Mar 31, Apr 1, Mar 31, Apr 1, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ 210 $ (143 ) $ 209 $ (72 ) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 56 28 54 27 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 329 (399 ) — — — — Hedged item (329 ) 399 — — — — Foreign exchange contracts — (7 ) — — — — Hedged item — 8 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 23 (5 ) — — The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness — — 41 2 24 6 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (d) — — 35 (42 ) — — Foreign currency long-term debt (d) — — 38 (92 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (120 ) (55 ) — — — — All other net — — 1 — — — $ (120 ) $ (55 ) $ 404 $ (251 ) $ 286 $ (39 ) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income–– Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net. (c) Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $202 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (d) Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.1 billion as of March 31, 2019 , which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $2.0 billion as of March 31, 2019 , which are used as hedging instruments in net investment hedges.
Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges	The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended (MILLIONS OF DOLLARS) March 31, 2019 April 1, 2018 Cost of sales $ 2,433 $ 2,563 Other (income)/deductions—net 92 (178 )
Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges	The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended (MILLIONS OF DOLLARS) March 31, 2019 April 1, 2018 Cost of sales $ 2,433 $ 2,563 Other (income)/deductions—net 92 (178 ) The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: March 31, 2019 April 1, 2018 (MILLIONS OF DOLLARS) Carrying Amount of Hedged Assets/Liabilities Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets/Liabilities Carrying Amount of Hedged Assets/Liabilities Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets/Liabilities Short-term investments $ — $ — $ 286 $ (1 ) Long-term investments 45 (1 ) 45 (1 ) Short-term borrowings, including current portion of long-term debt 1,500 1 999 1 Long-term debt 9,945 (282) 11,372 100

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) March 31, December 31, Finished goods $ 2,287 $ 2,262 Work-in-process 5,182 4,701 Raw materials and supplies 560 546 Inventories (a) $ 8,029 $ 7,508 Noncurrent inventories not included above (b) $ 637 $ 618 (a) The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery and market demand. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.
Schedule of Components of Inventories, Noncurrent	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) March 31, December 31, Finished goods $ 2,287 $ 2,262 Work-in-process 5,182 4,701 Raw materials and supplies 560 546 Inventories (a) $ 8,029 $ 7,508 Noncurrent inventories not included above (b) $ 637 $ 618 (a) The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery and market demand. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset_2

Identifiable Intangible Assets and Goodwill (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : March 31, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 89,379 $ (59,913 ) $ 29,465 $ 89,430 $ (58,895 ) $ 30,535 Brands 923 (717 ) 206 923 (708 ) 215 Licensing agreements and other 1,442 (1,150 ) 292 1,436 (1,140 ) 296 91,743 (61,780 ) 29,963 91,788 (60,743 ) 31,045 Indefinite-lived intangible assets Brands and other 1,994 1,994 1,994 1,994 IPR&D 2,082 2,082 2,171 2,171 4,076 4,076 4,165 4,165 Identifiable intangible assets (a) $ 95,819 $ (61,780 ) $ 34,039 $ 95,954 $ (60,743 ) $ 35,211 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization and intangible asset impairment charges, partially offset by additions for the period. See Note 4 for additional information on intangible asset impairments.
Schedule of Indefinite Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : March 31, 2019 December 31, 2018 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 89,379 $ (59,913 ) $ 29,465 $ 89,430 $ (58,895 ) $ 30,535 Brands 923 (717 ) 206 923 (708 ) 215 Licensing agreements and other 1,442 (1,150 ) 292 1,436 (1,140 ) 296 91,743 (61,780 ) 29,963 91,788 (60,743 ) 31,045 Indefinite-lived intangible assets Brands and other 1,994 1,994 1,994 1,994 IPR&D 2,082 2,082 2,171 2,171 4,076 4,076 4,165 4,165 Identifiable intangible assets (a) $ 95,819 $ (61,780 ) $ 34,039 $ 95,954 $ (60,743 ) $ 35,211 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization and intangible asset impairment charges, partially offset by additions for the period. See Note 4 for additional information on intangible asset impairments.
Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: March 31, 2019 Biopharma Upjohn WRDM Developed technology rights 99 % 1 % — Brands, finite-lived 100 % — — Brands, indefinite-lived 42 % 58 % — IPR&D 87 % — 13 %
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) Biopharma Upjohn To be Allocated (a) Total Balance, December 31, 2018 $ — $ — $ 53,411 $ 53,411 Other (b) — — 76 76 Balance, March 31, 2019 $ — $ — $ 53,487 $ 53,487 (a) The amount to be allocated includes the goodwill associated with our former operating segments (see above), for which the allocation to our new reporting units, and, as a result, to the new operating segments, is pending. (b) Primarily reflects the impact of foreign exchange.

Pension and Postretirement Be_2

Pension and Postretirement Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2019
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following table provides the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) March 31, 2019 April 1, 2018 March 31, 2019 April 1, 2018 March 31, 2019 April 1, 2018 March 31, 2019 April 1, 2018 Net periodic benefit cost/(credit): Service cost $ — $ — $ — $ — $ 32 $ 37 $ 9 $ 10 Interest cost 157 151 12 13 54 54 19 18 Expected return on plan assets (223 ) (263 ) — — (80 ) (92 ) (8 ) (9 ) Amortization of: Actuarial losses 37 30 2 4 20 26 1 2 Prior service credits (1 ) — — — (1 ) (1 ) (45 ) (45 ) Curtailments — 2 — — — — — (7 ) Settlements 1 20 — 17 — — — — Special termination benefits — — 6 — — — — — $ (28 ) $ (58 ) $ 20 $ 33 $ 25 $ 24 $ (23 ) $ (31 ) The following table provides the amounts we contributed, and the amounts we expect to contribute during 2019, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the three months ended March 31, 2019 $ 1 $ 71 $ 44 $ 29 Expected contributions from our general assets during 2019 (a) 10 167 191 149
Schedule of Employer Contributions to Pension and Postretirement Plans	The following table provides the amounts we contributed, and the amounts we expect to contribute during 2019, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the three months ended March 31, 2019 $ 1 $ 71 $ 44 $ 29 Expected contributions from our general assets during 2019 (a) 10 167 191 149 (a) Contributions expected to be made for 2019 are inclusive of amounts contributed during the three months ended March 31, 2019. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Att_2

Earnings Per Common Share Attributable to Common Shareholders (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of EPS : Three Months Ended (IN MILLIONS) March 31, April 1, EPS Numerator––Basic Income from continuing operations $ 3,889 $ 3,571 Less: Net income attributable to noncontrolling interests 6 9 Income from continuing operations attributable to Pfizer Inc. 3,884 3,562 Less: Preferred stock dividends––net of tax — — Income from continuing operations attributable to Pfizer Inc. common shareholders 3,883 3,562 Discontinued operations––net of tax — (1 ) Net income attributable to Pfizer Inc. common shareholders $ 3,883 $ 3,560 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,884 $ 3,562 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — (1 ) Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,884 $ 3,561 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,635 5,957 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements 115 100 Weighted-average number of common shares outstanding––Diluted 5,750 6,057 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a) 2 2 Cash dividends declared per share $ 0.36 $ 0.34 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Segment, Geographic and Other_2

Segment, Geographic and Other Revenue Information (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) March 31, April 1, March 31, April 1, Reportable Segments: Biopharma $ 9,185 $ 8,881 $ 5,888 $ 5,823 Upjohn 3,075 3,120 2,274 2,168 Total reportable segments 12,259 12,001 8,162 7,991 Other business activities — — (1,113 ) (1,187 ) Reconciling Items: Corporate and other unallocated 858 905 (1,278 ) (1,325 ) Purchase accounting adjustments — — (1,038 ) (1,221 ) Acquisition-related costs — — (28 ) (48 ) Certain significant items (b) — — (382 ) (83 ) $ 13,118 $ 12,906 $ 4,323 $ 4,127 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $64 million in the first quarter of 2019 and $59 million in the first quarter of 2018 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the first quarter of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction ini tiatives that are not associated with an acquisition of $57 million , (ii) income for certain legal matters of $6 million , (iii) certain asset impairment charges of $139 million , (iv) charges for business and legal entity alignment of $119 million , (v) net gains recognized during the period on investments in equity securities of $111 million , (vi) net losses on early retirement of debt of $138 million and (vii) other charges of $46 million . For additional information, see Note 3 and Note 4. For Earnings in the first quarter of 2018 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $51 million , (ii) income for certain legal matters of $19 million , (iii) charges for business and legal entity alignment of $3 million , (iv) net gains recognized during the period on investments in equity securities of $118 million , (v) net losses on early retirement of debt of $3 million and (vi) other charges of $162 million , which includes, among other things, a $108 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA. For additional information, see Note 3 and Note 4 .
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) March 31, April 1, March 31, April 1, Reportable Segments: Biopharma $ 9,185 $ 8,881 $ 5,888 $ 5,823 Upjohn 3,075 3,120 2,274 2,168 Total reportable segments 12,259 12,001 8,162 7,991 Other business activities — — (1,113 ) (1,187 ) Reconciling Items: Corporate and other unallocated 858 905 (1,278 ) (1,325 ) Purchase accounting adjustments — — (1,038 ) (1,221 ) Acquisition-related costs — — (28 ) (48 ) Certain significant items (b) — — (382 ) (83 ) $ 13,118 $ 12,906 $ 4,323 $ 4,127 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $64 million in the first quarter of 2019 and $59 million in the first quarter of 2018 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the first quarter of 2019 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction ini tiatives that are not associated with an acquisition of $57 million , (ii) income for certain legal matters of $6 million , (iii) certain asset impairment charges of $139 million , (iv) charges for business and legal entity alignment of $119 million , (v) net gains recognized during the period on investments in equity securities of $111 million , (vi) net losses on early retirement of debt of $138 million and (vii) other charges of $46 million . For additional information, see Note 3 and Note 4. For Earnings in the first quarter of 2018 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $51 million , (ii) income for certain legal matters of $19 million , (iii) charges for business and legal entity alignment of $3 million , (iv) net gains recognized during the period on investments in equity securities of $118 million , (v) net losses on early retirement of debt of $3 million and (vi) other charges of $162 million , which includes, among other things, a $108 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA. For additional information, see Note 3 and Note 4 .
Schedule of Revenues by Geographic Region	The following table provides revenues by geographic area: Three Months Ended (MILLIONS OF DOLLARS) March 31, April 1, % Change U.S. $ 6,175 $ 6,275 (2 ) Developed Europe (a) 2,086 2,092 — Developed Rest of World (b) 1,535 1,461 5 Emerging Markets (c) 3,322 3,078 8 Revenues $ 13,118 $ 12,906 2 (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the first quarter of 2019 and 2018 . (b) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey.
Schedule of Significant Product Revenues	The following table provides detailed revenue information: (MILLIONS OF DOLLARS) Three Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS March 31, April 1, TOTAL REVENUES $ 13,118 $ 12,906 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) (a) $ 9,185 $ 8,881 Internal Medicine (b) $ 2,217 $ 2,071 Eliquis alliance revenues and direct sales Atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,011 765 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 273 251 Premarin family Symptoms of menopause 168 191 BMP2 Development of bone and cartilage 67 73 Toviaz Overactive bladder 60 60 All other Internal Medicine Various 639 730 Oncology (c) $ 1,961 $ 1,760 Ibrance Advanced breast cancer 1,133 933 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 232 262 Xtandi alliance revenues Castration-resistant prostate cancer 168 159 Xalkori ALK-positive and ROS1-positive advanced NSCLC 123 153 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 80 60 Inlyta Advanced RCC 73 74 All other Oncology Various 153 119 Hospital (d) $ 1,887 $ 2,026 Sulperazon Treatment of infections 177 168 Medrol (e) Steroid anti-inflammatory 120 136 Zithromax (e) Bacterial infections 104 101 Vfend (e) Fungal infections 85 98 EpiPen Epinephrine injection used in treatment of life-threatening allergic reactions 66 52 Zyvox (e) Bacterial infections 64 68 Fragmin Slows blood clotting 60 70 Zosyn/Tazocin Antibiotic 51 61 Pfizer CentreOne (f) Various 176 171 All other Anti-infectives Various 354 392 All other Hospital (d) Various 631 708 Vaccines $ 1,612 $ 1,463 Prevnar 13/Prevenar 13 Vaccines for prevention of pneumococcal disease 1,486 1,380 All other Vaccines Various 126 83 Inflammation & Immunology (I&I) (g) $ 1,037 $ 1,013 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 451 506 Xeljanz RA, PsA, UC 423 326 Inflectra/Remsima Inflammatory diseases 138 145 Eucrisa Mild-to-moderate atopic dermatitis (eczema) 22 26 All other I&I Various 3 11 Rare Disease $ 470 $ 549 BeneFIX Hemophilia 125 147 Genotropin Replacement of human growth hormone 107 132 Refacto AF/Xyntha Hemophilia 106 130 Somavert Acromegaly 59 63 All other Rare Disease Various 72 76 (MILLIONS OF DOLLARS) Three Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS March 31, April 1, UPJOHN (b) , (h) $ 3,075 $ 3,120 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 1,186 1,213 Lipitor Reduction of LDL cholesterol 622 511 Norvasc Hypertension 300 256 Celebrex Arthritis pain and inflammation, acute pain 174 145 Viagra Erectile dysfunction 145 187 Effexor Depression and certain anxiety disorders 77 71 Zoloft Depression and certain anxiety disorders 69 74 Xalatan/Xalacom Glaucoma and ocular hypertension 62 72 All other Upjohn Various 440 591 CONSUMER HEALTHCARE BUSINESS (i) $ 858 $ 905 Total Alliance revenues Various $ 1,090 $ 855 (a) The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Hospital. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne (f) . (b) We reclassified certain products from the Legacy Established Products (LEP) category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 product revenues to the current presentation. (c) We performed certain reclassifications in the All other Oncology category to conform 2018 product revenues to the current presentation. (d) Hospital is a new business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy Sterile Injectables Pharmaceuticals (SIP) category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 product revenues to the current presentation. Hospital also includes Pfizer CentreOne (f) . All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (e) 2018 revenues for Medrol, Zithromax, Vfend and Zyvox may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category. (f) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne. (g) We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2018 product revenues to the current presentation. (h) Pfizer’s Upjohn business encompasses primarily off-patent branded and generic established medicines that includes 20 of our primarily off-patent solid oral dose legacy brands including Lyrica, Lipitor, Norvasc, Celebrex and Viagra, as well as certain generic medicines. (i) Pfizer’s Consumer Healthcare business is an over-the-counter medicines business, which we announced in December 2018 will be contributed to, and combined with, GSK’s consumer healthcare business to form a new consumer healthcare joint venture, of which we will own 32% , subject to customary closing conditions, including GSK shareholder approval, which occurred on May 8, 2019, and required regulatory approvals.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies (Details) $ in Millions	Jan. 01, 2019USD ($)Accounting_standard	Mar. 31, 2019USD ($)Operating_Segment	Dec. 31, 2018USD ($)Operating_Segment	Jan. 01, 2018Accounting_standard
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of accounting standards adopted | Accounting_standard	4			11
Number of business segments | Operating_Segment		3	2
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
ROU assets		$ 1,280
Lease liabilities (long-term)		1,043
Accrued rebates and other accruals		5,544	$ 5,426
Variable lease payments		$ 59
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
ROU assets	$ 1,400
Lease liabilities (long-term)	1,400
Cumulative effect adjustment to retained earnings, pre-tax	30
Cumulative effect adjustment to retained earnings, after-tax	$ 20
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease term		1 year
Operating lease term, option to extend		5 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease term		30 years
Operating lease term, option to extend		10 years

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Impact of Lease Standard Adoption (Details) - USD ($) $ in Millions	Mar. 31, 2019	[1]	Jan. 01, 2019	Dec. 31, 2018	[1]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other current assets	$ 2,567		$ 2,460	$ 2,461
Noncurrent deferred tax assets and other noncurrent tax assets	1,946		1,913	1,924
Other noncurrent assets	4,333		4,149	2,799
Other current liabilities	10,276		11,011	10,753
Other noncurrent liabilities	6,346		6,910	5,850
Retained earnings	$ 93,388		89,574	$ 89,554
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other current assets			(1)
Noncurrent deferred tax assets and other noncurrent tax assets			(11)
Other noncurrent assets			1,351
Other current liabilities			258
Other noncurrent liabilities			1,060
Retained earnings			$ 20
[1]	Amounts may not add due to rounding.

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 5,544	$ 5,426
Trade accounts receivable, less allowance for doubtful accounts [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	1,232	1,288
Other current liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates	3,344	3,208
Other accruals	559	531
Other noncurrent liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 410	$ 399

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - ROU Assets and Liabilities Presented in Balance Sheet (Details) $ in Millions	Mar. 31, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ROU assets	$ 1,280
Lease liabilities (short-term)	253
Lease liabilities (long-term)	$ 1,043

Basis of Presentation and Sig_8

Basis of Presentation and Significant Accounting Policies - Total Lease Costs (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating lease cost	$ 100
Variable lease cost	59
Sublease income	(10)
Total lease cost	$ 149

Basis of Presentation and Sig_9

Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies - Other Supplemental Lease Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating leases, weighted-average remaining contractual lease term	7 years 6 months
Operating lease, weighted-average discount rate	3.70%
Operating cash flows from operating leases	$ 78
ROU assets obtained in exchange for new operating lease liabilities	$ 46

Basis of Presentation and Si_10

Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2019	Apr. 30, 2018
Operating Lease Liabilities, Payments, Due, Rolling Maturity [Abstract]
Next one year	[1]				$ 287
1-2 years					241
2-3 years					207
3-4 years					175
4-5 years					144
Thereafter					435
Total undiscounted lease payments					1,489
Less: Imputed interest					193
Present Value of Minimum Lease Payments					1,296
Less: Current portion					253
Noncurrent portion					$ 1,043
Rental expense, net of sublease income		$ 301	$ 314	$ 292
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2019		300
2020		252
2021		210
2022		267
2023		248
After 2023		$ 2,040
Office Building In Hudson Yards Neighborhood Of New York City [Member]
Operating Lease Liabilities, Payments, Due, Rolling Maturity [Abstract]
Term of corporate headquarters lease agreement						20 years
Future minimum commitment for corporate headquarters lease						$ 1,700
[1]	Reflects lease payments due within 12 months subsequent to the balance sheet date.

Assets and Liabilities Held f_3

Assets and Liabilities Held for Sale (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total Consumer Healthcare liabilities held for sale	[1]	$ 1,935			$ 1,890
Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other assets held for sale	[2]	47			46
Assets held for sale		9,877			9,725
Consumer Healthcare [Member] | Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents		61			32
Trade accounts receivable, less allowance for doubtful accounts		550			532
Inventories		563			538
Other current assets		57			56
PP&E		687			675
Identifiable intangible assets, less accumulated amortization		5,776			5,763
Goodwill		1,972			1,972
Noncurrent deferred tax assets and other noncurrent tax assets		59			54
Other noncurrent assets		105			57
Assets held for sale		9,830			9,678
Trade accounts payable		335			406
Income taxes payable		55			39
Accrued compensation and related items		140			93
Other current liabilities		371			353
Pension benefit obligations, net		39			39
Postretirement benefit obligations, net		33			33
Noncurrent deferred tax liabilities		884			870
Other noncurrent liabilities		78			56
Total Consumer Healthcare liabilities held for sale		1,935			$ 1,890
Pre-tax income on a management business unit basis		$ 281	$ 265
Forecast [Member] | GSK Consumer Healthcare [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity method investment, ownership percentage				32.00%
GSK [Member] | Forecast [Member] | GSK Consumer Healthcare [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity method investment, ownership percentage				68.00%
[1]	Amounts may not add due to rounding.
[2]	Other assets held for sale consist of PP&E.

Restructuring Charges and Oth_3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)Operating_Segment	Dec. 31, 2018Operating_Segment
Restructuring Cost and Reserve [Line Items]
Number of business segments | Operating_Segment	3	2
Restructuring costs incurred	$ 92
2017 Through 2019 Initiatives And Organizing For Growth [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost	$ 800
Percentage of expected costs to be non-cash	20.00%
Restructuring costs incurred	$ 64
Manufacturing Plant Network Optimization [Member] | 2017 Through 2019 Initiatives And Organizing For Growth [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	735
Other Activities [Member] | 2017 Through 2019 Initiatives And Organizing For Growth [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	793
Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	3
Hospira [Member] | Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred	$ 25

Restructuring Charges and Oth_4

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Restructuring charges:
Employee terminations		$ (2)	$ (8)
Asset impairments		9	2
Exit costs		3	(3)
Restructuring charges/(credits)	[1]	10	(9)
Integration costs	[2]	36	52
Restructuring charges and certain acquisition-related costs	[3]	46	43
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[4]	13	17
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[5]	26	39
Total costs associated with acquisitions and cost-reduction/productivity initiatives		92	131
Other (Income)/Deductions, Net [Member]
Restructuring charges:
Net periodic pension and postretirement benefit costs recorded in Other (income)/deductions––net		6	32
Cost of Sales [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[4]	9	17
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[5]	13	16
Selling, Informational and Administrative Expenses [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[4]	1	0
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[5]	9	17
Research and Development Expense [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[4]	3	0
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[5]	$ 4	$ 6
[1]	In the first quarter of 2019, restructuring charges are primarily associated with cost reduction initiatives and mainly represent asset write downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. In the three months ended April 1, 2018, restructuring credits were primarily due to the reversal of previously recorded accruals for exit costs related to our acquisition of Hospira, as well as cost-reduction and productivity initiatives not associated with acquisitions.The restructuring activities for the three months ended March 31, 2019 are associated with the following:•Biopharma ($13 million charge); Upjohn ($13 million credit); and Other ($10 million charge). The restructuring activities for the three months ended April 1, 2018 are associated with the following:•Total reportable segments ($14 million credit); and Other ($4 million charge). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
[2]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the first quarter of 2019 and 2018, integration costs were primarily related to our acquisition of Hospira.
[3]	Amounts may not add due to rounding.
[4]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth_5

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)	[1]	$ 10	$ (9)
Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		10	4
Biopharma [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		13
Upjohn [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		$ (13)
Biopharma and Upjohn [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)			$ (14)
[1]	In the first quarter of 2019, restructuring charges are primarily associated with cost reduction initiatives and mainly represent asset write downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. In the three months ended April 1, 2018, restructuring credits were primarily due to the reversal of previously recorded accruals for exit costs related to our acquisition of Hospira, as well as cost-reduction and productivity initiatives not associated with acquisitions.The restructuring activities for the three months ended March 31, 2019 are associated with the following:•Biopharma ($13 million charge); Upjohn ($13 million credit); and Other ($10 million charge). The restructuring activities for the three months ended April 1, 2018 are associated with the following:•Total reportable segments ($14 million credit); and Other ($4 million charge). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.

Restructuring Charges and Oth_6

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018	[1]	$ 1,252
Provision/(Credit)	[2]	10	$ (9)
Utilization and other	[3]	(169)
Balance, March 31, 2019	[4]	1,093
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018	[1]	1,203
Provision/(Credit)		(2)
Utilization and other	[3]	(145)
Balance, March 31, 2019	[4]	1,057
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018	[1]	0
Provision/(Credit)		9
Utilization and other	[3]	(9)
Balance, March 31, 2019	[4]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018	[1]	49
Provision/(Credit)		3
Utilization and other	[3]	(15)
Balance, March 31, 2019	[4]	$ 37
[1]	Included in Other current liabilities ($823 million) and Other noncurrent liabilities ($428 million).
[2]	In the first quarter of 2019, restructuring charges are primarily associated with cost reduction initiatives and mainly represent asset write downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. In the three months ended April 1, 2018, restructuring credits were primarily due to the reversal of previously recorded accruals for exit costs related to our acquisition of Hospira, as well as cost-reduction and productivity initiatives not associated with acquisitions.The restructuring activities for the three months ended March 31, 2019 are associated with the following:•Biopharma ($13 million charge); Upjohn ($13 million credit); and Other ($10 million charge). The restructuring activities for the three months ended April 1, 2018 are associated with the following:•Total reportable segments ($14 million credit); and Other ($4 million charge). At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ($669 million) and Other noncurrent liabilities ($424 million).

Restructuring Charges and Oth_7

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Mar. 31, 2019		Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 1,093	[1]	$ 1,252	[2]
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	669		823
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 424		$ 428
[1]	Included in Other current liabilities ($669 million) and Other noncurrent liabilities ($424 million).
[2]	Included in Other current liabilities ($823 million) and Other noncurrent liabilities ($428 million).

Other (Income)_Deductions - N_3

Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Other Income and Expenses [Abstract]
Interest income	[1]	$ (66)	$ (77)
Interest expense	[1]	361	310
Net interest expense		295	233
Royalty-related income		(89)	(96)
Net gains on asset disposals		(1)	(7)
Net gains recognized during the period on investments in equity securities	[2],[3]	(111)	(118)
Net realized (gains)/losses on sales of investments in debt securities		0	3
Income from collaborations, out-licensing arrangements and sales of compound/product rights	[4]	(82)	(142)
Net periodic benefit credits other than service costs	[5]	(40)	(82)
Certain legal matters, net		4	(19)
Certain asset impairments	[6]	150	0
Business and legal entity alignment costs	[7]	119	3
Net losses on early retirement of debt	[8]	138	3
Other, net	[9]	(291)	42
Other (income)/deductions––net	[10]	$ 92	$ (178)
[1]	Interest income decreased in the first quarter of 2019, primarily driven by a lower investment balance. Interest expense increased in the first quarter of 2019, primarily as a result of higher interest rates.
[2]	The net gains on investments in equity securities are reported in Other (income)/deductions––net. For additional information, see Note 4.
[3]	The net gains on investments in equity securities for the first quarter of 2019 include gains of $43 million related to our investment in Allogene. The first quarter of 2018 included gains of $61 million related to our investment in ICU Medical stock. For additional information, see Note 7B.
[4]	Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first quarter of 2019, primarily includes $60 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub®, a generic of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder). In the first quarter of 2018, primarily includes, among other things, a $75 million milestone payment received from Shire related to their first dosing of a patient in a Phase III clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis, and a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU.
[5]	For additional information, see Note 10.
[6]	In the first quarter of 2019, primarily includes intangible asset impairment charges of $130 million composed of: (i) $90 million related to WRDM IPR&D, which relates to a pre-clinical stage asset from our acquisition of Bamboo Therapeutics, Inc. (Bamboo) for gene therapies for the potential treatment of patients with certain rare diseases; and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products. The WRDM IPR&D intangible asset impairment charge was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development. The intangible asset impairment charge related to the Biopharma developed technology right reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first quarter of 2019 includes other asset impairments of $20 million.
[7]	In the first quarter of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In the first quarter of 2018, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.
[8]	In first quarter of 2019, represents net losses due to the early retirement of debt, inclusive of the related termination of cross-currency swaps.
[9]	In the first quarter of 2019, includes among other things, credits of $72 million, reflecting the change in the fair value of contingent consideration, and dividend income of $64 million from our investment in ViiV. In the first quarter of 2018, primarily includes, among other things, charges of $102 million, reflecting the change in the fair value of contingent consideration, partially offset by dividend income of $59 million from our investment in ViiV.The following table provides additional information about the intangible assets that were impaired in the first quarter of 2019 in Other (income)/deductions: Fair Value(a) Three Months Ended March 31, 2019(MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 ImpairmentIntangible assets––IPR&D(b) $— $— $— $— $90Intangible assets––Developed technology right(b) — — — — 40Total $— $— $— $— $130
[10]	Amounts may not add due to rounding.

Other (Income)_Deductions - N_4

Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Loss Contingencies [Line Items]
Gains related to equity securities	[1],[2]	$ 111	$ 118
Intangible asset impairment charge		130
Other asset impairments		20
Change in fair value of contingent consideration		(72)	102
Allogene [Member]
Loss Contingencies [Line Items]
Gains related to equity securities		43
ViiV Healthcare Limited [Member]
Loss Contingencies [Line Items]
Dividend income		64	59
Mylan [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received		60
Shire [Member] | Licensing Arrangement [Member]
Loss Contingencies [Line Items]
Proceeds from licensing arrangement			75
Merck [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received			40
Disposed of by Sale [Member] | HIS [Member]
Loss Contingencies [Line Items]
Gains related to equity securities			$ 61
In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge	[3]	90
Pfizer's Worldwide Research, Development And Medical [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge		90
Biopharma [Member] | Operating Segments [Member] | Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge	[3]	$ 40
[1]	The net gains on investments in equity securities are reported in Other (income)/deductions––net. For additional information, see Note 4.
[2]	The net gains on investments in equity securities for the first quarter of 2019 include gains of $43 million related to our investment in Allogene. The first quarter of 2018 included gains of $61 million related to our investment in ICU Medical stock. For additional information, see Note 7B.
[3]	Reflects intangible assets written down to fair value in the first three months of 2019. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Other (Income)_Deductions - N_5

Other (Income)/Deductions - Net - Intangible Assets (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Finite-Lived Intangible Assets [Line Items]
Impairment	$ 130
Total	0	[1]
Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-Developed technology right	0	[1],[2]
Level 1 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	0	[1]
Level 1 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-Developed technology right	0	[1],[2]
Level 2 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	0	[1]
Level 2 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-Developed technology right	0	[1],[2]
Level 3 [Member]
Finite-Lived Intangible Assets [Line Items]
Total	0	[1]
Level 3 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-Developed technology right	0	[1],[2]
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-IPR&D	0	[1],[2]
Impairment	90	[2]
In Process Research and Development [Member] | Level 1 [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-IPR&D	0	[1],[2]
In Process Research and Development [Member] | Level 2 [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-IPR&D	0	[1],[2]
In Process Research and Development [Member] | Level 3 [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets-IPR&D	$ 0	[1],[2]
[1]	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.
[2]	Reflects intangible assets written down to fair value in the first three months of 2019. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Apr. 30, 2019	Mar. 31, 2019	Apr. 01, 2018
Income Taxes [Line Items]
Effective tax rate for income from continuing operations		10.00%	13.50%
Repatriation tax liability		$ 15,000
Income Taxes Payable [Member]
Income Taxes [Line Items]
Repatriation tax liability		$ 750
Subsequent Event [Member]
Income Taxes [Line Items]
First installment for repatriation tax	$ 750

Tax Matters (Detail)

Tax Matters (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Foreign currency translation adjustments, net	[1]	$ 27	$ (34)
Unrealized holding gains/(losses) on derivative financial instruments, net		59	(4)
Reclassification adjustments for (gains)/losses included in net income		(55)	(7)
Derivatives qualifying as hedges, tax, total		4	(9)
Unrealized holding gains on available-for-sale securities, net		5	20
Reclassification adjustments for (gains)/losses included in net income		1	(22)
Available-for-sale securities, tax, total		7	(47)
Benefit plans: actuarial gains, net		0	38
Reclassification adjustments related to amortization		3	14
Reclassification adjustments related to settlements, net		0	9
Other		(5)	(20)
Defined benefit plans, actuarial gain (loss), tax, total		(2)	677
Reclassification adjustments related to amortization of prior service costs and other, net		(11)	(11)
Reclassification adjustments related to curtailments of prior service costs and other, net		0	(7)
Other		0	6
Pension and other postretirement benefit plans, net prior service cost (credit), tax		(11)	(155)
Tax provision on other comprehensive income	[2]	25	432
ASU 2018-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[3]	0	1
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[3]	0	637
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[3]	0	(144)
ASU 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings	[4]	$ 0	$ (45)
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	Amounts may not add due to rounding.
[3]	For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.
[4]	For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	$ 63,407	[1]
Balance, March 31, 2019	58,806	[1]
Foreign currency translation adjustments loss attributable to noncontrolling interests	4
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	(11,275)
Other comprehensive income/(loss)	353	[2]
Balance, March 31, 2019	(10,923)
Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	(6,075)
Other comprehensive income/(loss)	304	[2]
Balance, March 31, 2019	(5,772)
Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	167
Other comprehensive income/(loss)	0	[2]
Balance, March 31, 2019	167
Cash flow hedge gain to be reclassified within twelve months	345
Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	(68)
Other comprehensive income/(loss)	44	[2]
Balance, March 31, 2019	(24)
Actuarial Gains/(Losses) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	(6,027)
Other comprehensive income/(loss)	40	[2]
Balance, March 31, 2019	(5,986)
Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2018	728
Other comprehensive income/(loss)	(35)	[2]
Balance, March 31, 2019	$ 693
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $4 million loss for the first three months of 2019.

Financial Instruments - Financi

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		$ 1,597	$ 1,600
Total assets	[1]	155,421	159,422
Total liabilities		501	1,024
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		11,845	19,595
Total liabilities		501	1,024
Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		1,597	1,600
Available-for-sale debt securities		7,180	15,091
Total short-term investments		8,776	16,691
Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		563	574
Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		81	97
Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		482	477
Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		434	491
Trading funds and securities		1,341	1,273
Total long-term investments		1,775	1,764
Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		731	566
Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		461	335
Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		269	232
Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		91	82
Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		2	5
Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		89	78
Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		410	942
Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		178	378
Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		232	564
Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		1,333	1,260
Total liabilities		0	0
Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		16	17
Available-for-sale debt securities		0	0
Total short-term investments		16	17
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Trading funds and securities		1,317	1,243
Total long-term investments		1,317	1,243
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		10,512	18,335
Total liabilities		501	1,024
Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		1,581	1,583
Available-for-sale debt securities		7,180	15,091
Total short-term investments		8,760	16,674
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		563	574
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		81	97
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		482	477
Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		434	491
Trading funds and securities		24	30
Total long-term investments		458	521
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		731	566
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		461	335
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		269	232
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		91	82
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		2	5
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		89	78
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		410	942
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		178	378
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		232	564
Money market funds [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		1,570	1,571
Money market funds [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		0	0
Money market funds [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		1,570	1,571
Equity [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	26	29
Equity [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	1,290	1,223
Equity [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	16	17
Equity [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	1,265	1,193
Equity [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	11	11
Equity [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	24	30
Trading Securities [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		52	50
Trading Securities [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		51	50
Trading Securities [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		0	0
Government and agency - non U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		5,451	9,703
Government and agency - non U.S. [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		5,406	9,609
Government and agency - non U.S. [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		44	94
Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		5,406	9,609
Government and agency - non U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		44	94
Corporate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	[3]	2,162	5,878
Corporate [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,773	5,482
Corporate [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		389	397
Corporate [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,773	5,482
Corporate [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		$ 389	$ 397
[1]	Amounts may not add due to rounding.
[2]	As of March 31, 2019, short-term equity securities of $10 million and long-term equity securities of $23 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2018, short-term equity securities of $11 million and long-term equity securities of $29 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
[3]	Primarily issued by a diverse group of corporations.

Financial Instruments - Finan_2

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail) - Recurring [Member] - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Footnotes to selected financial assets and liabilities:
Short-term equity securities held in trust	$ 10	$ 11
Long-term equity securities held in trust	$ 23	$ 29

Financial Instruments - Finan_3

Financial Instruments - Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	$ 35,733	$ 32,909
Estimated Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	39,016	35,260
Estimated Fair Value [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	$ 39,016	$ 35,260

Financial Instruments - Total S

Financial Instruments - Total Short-Term and Long-Term Investments (Details) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Financial Instruments [Abstract]
Equity securities		$ 1,597	$ 1,600
Available-for-sale debt securities		7,180	15,091
Held-to-maturity debt securities		906	1,003
Total Short-term investments	[1]	9,682	17,694
Equity securities		1,290	1,223
Trading equity funds securities		52	50
Available-for-sale debt securities		434	491
Held-to-maturity debt securities		55	59
Private equity investments at cost, as adjusted, or equity method		1,029	944
Total Long-term investments	[1]	2,859	2,767
Held-to-maturity cash equivalents		$ 213	$ 199
[1]	Amounts may not add due to rounding.

Financial Instruments - Investm

Financial Instruments - Investments (Details) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Debt securities, amortized cost		$ 8,815	$ 16,920
Debt securities, gross unrealized gains		7	8
Debt securities, gross unrealized losses		(34)	(85)
Available-for-sale securities and held-to-maturity securities		8,787	16,842
Debt securities maturities, within 1 year, fair value		8,299
Debt securities maturities, over 1 to 5 years, fair value		446
Debt securities maturities, over 5 years, fair value		43
Government and agency - non U.S. [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost		5,462	9,754
Available-for-sale debt securities, gross unrealized gains		6	7
Available-for-sale debt securities, gross unrealized losses		(17)	(58)
Available-for-sale debt securities, fair value		5,451	9,703
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		5,406
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		44
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale debt securities, fair value		5,451	9,703
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		557	592
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		557	592
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		557
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		0
Held-to-maturity securities, debt maturities, over 5 years, fair value		0
Held-to-maturity securities, debt maturities, total		557	592
Corporate [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost	[1]	2,178	5,905
Available-for-sale debt securities, gross unrealized gains	[1]	1	0
Available-for-sale debt securities, gross unrealized losses	[1]	(17)	(27)
Available-for-sale debt securities, fair value	[1]	2,162	5,878
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	[1]	1,773
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	[1]	386
Available-for-sale securities, debt maturities, over 5 years, fair value	[1]	3
Available-for-sale debt securities, fair value	[1]	2,162	5,878
Time deposits and other [Member]
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		617	668
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		617	668
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		562
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		16
Held-to-maturity securities, debt maturities, over 5 years, fair value		39
Held-to-maturity securities, debt maturities, total		$ 617	$ 668
[1]	Primarily issued by a diverse group of corporations.

Financial Instruments - Inves_2

Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Financial Instruments [Abstract]
Net gains recognized during the period on investments in equity securities	[1],[2]	$ (111)	$ (118)
Less: Net gains recognized during the period on equity securities sold during the period		(5)	(19)
Net unrealized gains during the reporting period on equity securities still held at the reporting date		$ (106)	$ (98)
[1]	The net gains on investments in equity securities are reported in Other (income)/deductions––net. For additional information, see Note 4.
[2]	The net gains on investments in equity securities for the first quarter of 2019 include gains of $43 million related to our investment in Allogene. The first quarter of 2018 included gains of $61 million related to our investment in ICU Medical stock. For additional information, see Note 7B.

Financial Instruments - Short-t

Financial Instruments - Short-term Borrowings (Details) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Financial Instruments [Abstract]
Commercial paper		$ 3,947	$ 3,100
Current portion of long-term debt, principal amount		4,473	4,781
Other short-term borrowings, principal amount	[1]	1,000	966
Total short-term borrowings, principal amount		9,420	8,847
Net fair value adjustments related to hedging and purchase accounting		(1)	(5)
Net unamortized discounts, premiums and debt issuance costs		(9)	(11)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted	[2]	$ 9,410	$ 8,831
[1]	Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E.
[2]	Amounts may not add due to rounding.

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt - New Issuances (Details) - Senior Notes [Member] - USD ($) $ in Millions		Mar. 31, 2019	Jun. 03, 2016
Debt Instrument [Line Items]
Principal	[1]	$ 5,000
Weighted-average effective interest rate			3.57%
2.800% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 500
Stated interest rate		2.80%
2.950% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 750
Stated interest rate		2.95%
3.450% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 1,750
Stated interest rate		3.45%
3.900% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 750
Stated interest rate		3.90%
4.000% notes [Member]
Debt Instrument [Line Items]
Principal	[2]	$ 1,250
Stated interest rate		4.00%
[1]	The weighted-average effective interest rate for the notes at issuance was 3.57%.
[2]	Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.

Financial Instruments - Long-_2

Financial Instruments - Long-Term Debt Narrative (Details) $ in Millions, € in Billions		1 Months Ended	3 Months Ended
		Jan. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Apr. 01, 2018USD ($)	Jan. 31, 2019EUR (€)
Debt Instrument [Line Items]
Loss on extinguishment of debt	[1]		$ 138	$ 3
5.75% notes [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 138
Senior Notes [Member] | 5.75% notes [Member]
Debt Instrument [Line Items]
Repurchase amount		$ 1,300			€ 1.1
Stated interest rate		5.75%			5.75%
Redemption value		$ 1,500			€ 1.3
[1]	In first quarter of 2019, represents net losses due to the early retirement of debt, inclusive of the related termination of cross-currency swaps.

Financial Instruments - Long-_3

Financial Instruments - Long-Term Debt (Details) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Net fair value adjustments related to hedging and purchase accounting		$ (1)	$ (5)
Net unamortized discounts, premiums and debt issuance costs		(9)	(11)
Total long-term debt, carried at historical proceeds, as adjusted	[1]	35,733	32,909
Current portion of long-term debt, carried at historical proceeds, as adjusted	[1]	4,471	4,776
Unsecured Debt [Member]
Debt Instrument [Line Items]
Total long-term debt, principal amount		35,122	32,558
Net fair value adjustments related to hedging and purchase accounting		793	479
Net unamortized discounts, premiums and debt issuance costs		(189)	(136)
Other long-term debt		7	7
Total long-term debt, carried at historical proceeds, as adjusted		35,733	32,909
Current portion of long-term debt, carried at historical proceeds, as adjusted		$ 4,471	$ 4,776
[1]	Amounts may not add due to rounding.

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Derivative [Line Items]
Asset		$ 1,294	$ 1,140
Liability		501	1,024
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Asset		1,255	1,085
Liability		429	968
Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	18,353	22,984
Asset	[1]	713	654
Liability	[1]	248	586
Designated as Hedging Instrument [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Notional		11,145	11,145
Asset		543	432
Liability		180	383
Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional		15,111	15,154
Asset		38	55
Liability		72	$ 55
Inventory sales [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	$ 6,500
[1]	As of March 31, 2019, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $6.5 billion.

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	$ (120)	$ (55)
Not Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	(120)	(55)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2],[3]	0	0
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach	[1],[2]	0	0
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	0	(7)
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	329	(399)
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts, hedged item gain/(loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	(329)	399
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts, hedged item gain (loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	0	8
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	0	0
The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness	[1],[2]	0	0
Net Investment Hedging, Nonderivative Instruments [Member] | OID [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2],[4]	0	0
Net Investment Hedging, Nonderivative Instruments [Member] | OID [Member] | Foreign currency Long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2],[4]	0	0
Other Derivative Instruments [Member] | OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	0	0
Amount of Gains/(Losses) Recognized in OCI [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2]	404	(251)
Amount of Gains/(Losses) Recognized in OCI [Member] | Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2]	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach	[1],[2]	56	28
Amount of Gains/(Losses) Recognized in OCI	[1],[2],[3]	210	(143)
Amount of Gains/(Losses) Recognized in OCI [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2]	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2]	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts, hedged item gain/(loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2]	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts, hedged item gain (loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2]	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness	[1],[2]	41	2
Amount of Gains/(Losses) Recognized in OCI	[1],[2]	23	(5)
Amount of Gains/(Losses) Recognized in OCI [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2],[4]	35	(42)
Amount of Gains/(Losses) Recognized in OCI [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency Long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2],[4]	38	(92)
Amount of Gains/(Losses) Recognized in OCI [Member] | Other Derivative Instruments [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[2]	1	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2]	286	(39)
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Not Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach	[1],[2]	54	27
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2],[3]	209	(72)
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts, hedged item gain/(loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts, hedged item gain (loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness	[1],[2]	24	6
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | OID [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2],[4]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | OID [Member] | Foreign currency Long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2],[4]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Other Derivative Instruments [Member] | OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[2]	$ 0	$ 0
[1]	For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income––Unrealized holding gains/(losses) on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net.
[2]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income. COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income.
[3]	Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $202 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043.
[4]	Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.1 billion as of March 31, 2019, which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $2.0 billion as of March 31, 2019, which are used as hedging instruments in net investment hedges.The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded:Three Months Ended(MILLIONS OF DOLLARS)March 31, 2019 April 1, 2018Cost of sales$2,433 $2,563Other (income)/deductions—net92 (178)

Financial Instruments - Deriv_2

Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Derivative [Line Items]
Pre-tax gain expected to be reclassified within the next 12 months		$ 202
Short-term debt	[1]	9,410	$ 8,831
Unsecured Debt [Member]
Derivative [Line Items]
Long-term debt		1,800
Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Short-term debt		1,100
Foreign currency Long-term debt [Member]
Derivative [Line Items]
Long-term debt		$ 2,000
[1]	Amounts may not add due to rounding.

Financial Instruments - Fair _2

Financial Instruments - Fair Value And Cash Flow Hedges (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Financial Instruments [Abstract]
Cost of sales	[1],[2]	$ 2,433	$ 2,563
Other (income)/deductions––net	[1]	$ 92	$ (178)
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Financial Instruments - Cumulat

Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($) $ in Millions	Mar. 31, 2019	Apr. 01, 2018
Short-term investments [Member]
Derivative [Line Items]
Carrying Amount of Hedged Assets	$ 0	$ 286
Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets	0	(1)
Long-term investments [Member]
Derivative [Line Items]
Carrying Amount of Hedged Assets	45	45
Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets	(1)	(1)
Short-term borrowings, including current portion of long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Hedged Liabilities	1,500	999
Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Liabilities	1	1
Long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Hedged Liabilities	9,945	11,372
Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Liabilities	$ (282)	$ 100

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) $ in Millions	Mar. 31, 2019USD ($)
Financial Instruments [Abstract]
Derivatives in a net liability position	$ 209
Collateral posted	214
Cash collateral received	$ 948

Financial Instruments - Credit

Financial Instruments - Credit Risk (Details) $ in Billions	3 Months Ended
	Mar. 31, 2019USD ($)
Bank sector [Member]
Concentration Risk [Line Items]
Maximum exposure, amount	$ 1.7

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Finished goods		$ 2,287	$ 2,262
Work-in-process		5,182	4,701
Raw materials and supplies		560	546
Inventories	[1],[2]	8,029	7,508
Noncurrent inventories not included above	[3]	$ 637	$ 618
[1]	Amounts may not add due to rounding.
[2]	The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery and market demand.
[3]	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset_3

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Mar. 31, 2019	Dec. 31, 2018
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		$ 4,076	$ 4,165
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		91,743	91,788
Finite-lived intangible assets, accumulated amortization	[1]	(61,780)	(60,743)
Finite-lived intangible assets, net		29,963	31,045
Intangible assets, gross carrying amount	[1]	95,819	95,954
Finite-lived intangible assets, accumulated amortization	[1]	(61,780)	(60,743)
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	34,039	35,211
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		1,994	1,994
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		2,082	2,171
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		89,379	89,430
Finite-lived intangible assets, accumulated amortization		(59,913)	(58,895)
Finite-lived intangible assets, net		29,465	30,535
Finite-lived intangible assets, accumulated amortization		(59,913)	(58,895)
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		923	923
Finite-lived intangible assets, accumulated amortization		(717)	(708)
Finite-lived intangible assets, net		206	215
Finite-lived intangible assets, accumulated amortization		(717)	(708)
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		1,442	1,436
Finite-lived intangible assets, accumulated amortization		(1,150)	(1,140)
Finite-lived intangible assets, net		292	296
Finite-lived intangible assets, accumulated amortization		$ (1,150)	$ (1,140)
[1]	The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization and intangible asset impairment charges, partially offset by additions for the period. See Note 4 for additional information on intangible asset impairments.
[2]	Amounts may not add due to rounding.

Identifiable Intangible Asset_4

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Mar. 31, 2019
Operating Segments [Member] | Developed Technology Rights [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	99.00%
Operating Segments [Member] | Developed Technology Rights [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	1.00%
Operating Segments [Member] | Brands [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	100.00%
Operating Segments [Member] | Brands [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%

Identifiable Intangible Asset_5

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Mar. 31, 2019
Biopharma [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	42.00%
Biopharma [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	87.00%
Upjohn [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	58.00%
Upjohn [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	13.00%

Identifiable Intangible Asset_6

Identifiable Intangible Assets and Goodwill - Narrative (Detail) $ in Billions	3 Months Ended		12 Months Ended
	Mar. 31, 2019USD ($)Operating_Segment	Apr. 01, 2018USD ($)	Dec. 31, 2018Operating_Segment
Finite-Lived Intangible Assets [Line Items]
Number of business segments | Operating_Segment	3		2
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets | $	$ 1.2	$ 1.2

Identifiable Intangible Asset_7

Identifiable Intangible Assets and Goodwill - Goodwill (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Goodwill [Roll Forward]
Balance, December 31, 2018	$ 53,411	[1]
Other	76	[2]
Balance, March 31, 2019	53,487	[1]
Operating Segments [Member] | Biopharma [Member]
Goodwill [Roll Forward]
Balance, December 31, 2018	0
Other	0	[2]
Balance, March 31, 2019	0
Operating Segments [Member] | Upjohn [Member]
Goodwill [Roll Forward]
Balance, December 31, 2018	0
Other	0	[2]
Balance, March 31, 2019	0
To Be Allocated [Member]
Goodwill [Roll Forward]
Balance, December 31, 2018	53,411	[3]
Other	76	[2],[3]
Balance, March 31, 2019	$ 53,487	[3]
[1]	Amounts may not add due to rounding.
[2]	Primarily reflects the impact of foreign exchange.
[3]	The amount to be allocated includes the goodwill associated with our former operating segments (see above), for which the allocation to our new reporting units, and, as a result, to the new operating segments, is pending.

Pension and Postretirement Be_3

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Apr. 01, 2018
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0
Interest cost	157	151
Expected return on plan assets	(223)	(263)
Amortization of:
Actuarial losses	37	30
Prior service costs/(credits)	(1)	0
Curtailments	0	2
Settlements	1	20
Special termination benefits	0	0
Defined benefit plan, net periodic benefit cost	(28)	(58)
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	32	37
Interest cost	54	54
Expected return on plan assets	(80)	(92)
Amortization of:
Actuarial losses	20	26
Prior service costs/(credits)	(1)	(1)
Curtailments	0	0
Settlements	0	0
Special termination benefits	0	0
Defined benefit plan, net periodic benefit cost	25	24
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0
Interest cost	12	13
Expected return on plan assets	0	0
Amortization of:
Actuarial losses	2	4
Prior service costs/(credits)	0	0
Curtailments	0	0
Settlements	0	17
Special termination benefits	6	0
Defined benefit plan, net periodic benefit cost	20	33
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	9	10
Interest cost	19	18
Expected return on plan assets	(8)	(9)
Amortization of:
Actuarial losses	1	2
Prior service costs/(credits)	(45)	(45)
Curtailments	0	(7)
Settlements	0	0
Special termination benefits	0	0
Defined benefit plan, net periodic benefit cost	$ (23)	$ (31)

Pension and Postretirement Be_4

Pension and Postretirement Benefit Plans (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 31, 2019	$ 1
Expected contributions from our general assets during 2019	10	[1]
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 31, 2019	44
Expected contributions from our general assets during 2019	191	[1]
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 31, 2019	71
Expected contributions from our general assets during 2019	167	[1]
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 31, 2019	29
Expected contributions from our general assets during 2019	$ 149	[1]
[1]	Contributions expected to be made for 2019 are inclusive of amounts contributed during the three months ended March 31, 2019. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Att_3

Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
EPS Numerator––Basic
Income from continuing operations	[1]	$ 3,889	$ 3,571
Less: Net income attributable to noncontrolling interests		6	9
Income from continuing operations attributable to Pfizer Inc.		3,884	3,562
Less: Preferred stock dividends––net of tax		0	0
Income from continuing operations attributable to Pfizer Inc. common shareholders		3,883	3,562
Discontinued operations––net of tax	[1]	0	(1)
Net income attributable to Pfizer Inc. common shareholders		3,883	3,560
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		3,884	3,562
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		0	(1)
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 3,884	$ 3,561
EPS Denominator
Weighted-average number of common shares outstanding––Basic	[1]	5,635	5,957
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)		115	100
Weighted-average number of common shares outstanding––Diluted	[1]	5,750	6,057
Cash dividends declared per share (in dollars per share)		$ 0.36	$ 0.34
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)	[2]	2	2
[1]	Amounts may not add due to rounding.
[2]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Com_2

Contingencies and Certain Commitments (Actions In Which We Are The Plaintiff) (Details)

1 Months Ended

3 Months Ended

Mar. 31, 2019Patents

Jun. 30, 2018Patents

Feb. 28, 2018Patents

Jan. 31, 2018Patents

Dec. 31, 2017Patents

Oct. 31, 2017Patents

Sep. 30, 2017Patents

Mar. 31, 2017Patents

Feb. 28, 2017Patents

Aug. 31, 2016Patents

Jun. 30, 2015Patents

Apr. 30, 2017PatentsDefendant

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

1

Number of patents not infringed upon

3

Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Precedex Premix [Member] | Hospira Versus Gland [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents not infringed upon

6

Precedex Premix [Member] | Hospira Versus Hengrui [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents not infringed upon

6

Precedex Premix [Member] | Hospira Versus Baxter [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Number of patents due to expire in 2019

1

Number of patents due to expire in 2032

3

Patent Infringement [Member] | Judicial Ruling [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

1

Patent Infringement [Member] | Pfizer Versus Ajanta [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Bosulif [Member] | Wyeth Versus Sun [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Prinston and Breckenridge [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Breckenridge [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents due to expire in December 2020

3

Number or patents due to expire in December 2025

1

Patent Infringement [Member] | Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Number of defendants | Defendant

25

Contingencies and Certain Com_3

Contingencies and Certain Commitments (Actions In Which We Are The Defendant) (Detail) £ in Millions	1 Months Ended
	Oct. 31, 2018manufacturer	Sep. 30, 2018lagoon	Mar. 31, 2015Patents	Mar. 31, 2013lagoon	Mar. 31, 2019Claim	Dec. 31, 2016GBP (£)
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon			6
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Claims dismissed			4
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon			2
Docetaxel [Member] | Pfizer And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants other than main defendant | manufacturer	8
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim					46,400
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim					1
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons | lagoon		2		2
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine | £						£ 84.2

Contingencies and Certain Com_4

Contingencies and Certain Commitments (Details) - USD ($) shares in Millions, $ in Billions	Feb. 12, 2019	Feb. 07, 2019	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Share repurchase agreement, amount		$ 6.8
Accelerated share repurchases, cash paid	$ 6.8
Shares repurchased	130
Accelerated share repurchases, shares repurchased during period, percentage of agreement amount		80.00%
Remaining authorized repurchase amount			$ 5.3

Segment, Geographic and Other_3

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		3 Months Ended	12 Months Ended
		Mar. 31, 2019USD ($)Operating_Segment	Dec. 31, 2018USD ($)Operating_Segment
Segment Reporting [Abstract]
Number of business segments | Operating_Segment		3	2
Assets | $	[1]	$ 155,421	$ 159,422
[1]	Amounts may not add due to rounding.

Segment, Geographic and Other_4

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Segment Reporting Information [Line Items]
Revenues	[1]	$ 13,118	$ 12,906
Earnings	[1],[2]	4,323	4,127
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		12,259	12,001
Earnings	[2]	8,162	7,991
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Earnings	[2]	(1,113)	(1,187)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Earnings	[2]	(1,038)	(1,221)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Earnings	[2]	(28)	(48)
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3]	(382)	(83)
Corporate [Member]
Segment Reporting Information [Line Items]
Revenues		858	905
Earnings	[2]	(1,278)	(1,325)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues	[4]	9,185	8,881
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		9,185	8,881
Earnings	[2]	5,888	5,823
Upjohn [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		3,075	3,120
Earnings	[2]	$ 2,274	$ 2,168
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $64 million in the first quarter of 2019 and $59 million in the first quarter of 2018 from our investment in ViiV. For additional information, see Note 4.
[3]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.For Earnings in the first quarter of 2019, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $57 million, (ii) income for certain legal matters of $6 million, (iii) certain asset impairment charges of $139 million, (iv) charges for business and legal entity alignment of $119 million, (v) net gains recognized during the period on investments in equity securities of $111 million, (vi) net losses on early retirement of debt of $138 million and (vii) other charges of $46 million. For additional information, see Note 3 and Note 4.For Earnings in the first quarter of 2018, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $51 million, (ii) income for certain legal matters of $19 million, (iii) charges for business and legal entity alignment of $3 million, (iv) net gains recognized during the period on investments in equity securities of $118 million, (v) net losses on early retirement of debt of $3 million and (vi) other charges of $162 million, which includes, among other things, a $108 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA. For additional information, see Note 3 and Note 4.
[4]	The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Hospital. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne(f).

Segment, Geographic and Other_5

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Segment Reporting Information [Line Items]
Income (charges) for certain legal matters		$ (4)	$ 19
Gains related to equity securities	[1],[2]	111	118
Loss on extinguishment of debt	[3]	138	3
Business and legal entity alignment costs	[4]	119	3
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost reduction and productivity initiatives excluding acquisition related costs		57	51
Income (charges) for certain legal matters	[4]	6	19
Other charges		46	162
Asset impairment charges		139
Business and legal entity alignment costs		119	3
Special one-time bonus paid to all non-executive Pfizer colleagues			108
ViiV Healthcare Limited [Member]
Segment Reporting Information [Line Items]
Dividend income		$ 64	$ 59
[1]	The net gains on investments in equity securities are reported in Other (income)/deductions––net. For additional information, see Note 4.
[2]	The net gains on investments in equity securities for the first quarter of 2019 include gains of $43 million related to our investment in Allogene. The first quarter of 2018 included gains of $61 million related to our investment in ICU Medical stock. For additional information, see Note 7B.
[3]	In first quarter of 2019, represents net losses due to the early retirement of debt, inclusive of the related termination of cross-currency swaps.
[4]	In the first quarter of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In the first quarter of 2018, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.

Segment, Geographic and Other_6

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 13,118	$ 12,906
Percentage Change In Revenue		2.00%
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 6,175	6,275
Percentage Change In Revenue		(2.00%)
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	$ 2,086	2,092
Percentage Change In Revenue		0.00%
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3]	$ 1,535	1,461
Percentage Change In Revenue	[3]	5.00%
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[4]	$ 3,322	$ 3,078
Percentage Change In Revenue	[4]	8.00%
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the first quarter of 2019 and 2018.
[3]	Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
[4]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey.

Segment, Geographic and Other_7

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 13,118	$ 12,906
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	2,086	2,092
Euro Member Countries, Euro [Member] | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 1,700	$ 1,700
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the first quarter of 2019 and 2018.

Segment, Geographic and Other_8

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Revenue from External Customer [Line Items]
Revenues	[1]	$ 13,118	$ 12,906
Biopharma, Upjohn And Consumer Healthcare Segments [Member]
Revenue from External Customer [Line Items]
Revenues		13,118	12,906
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		1,090	855
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	9,185	8,881
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	2,217	2,071
Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues		1,011	765
Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues		273	251
Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues		168	191
Internal Medicine [Member] | Biopharma [Member] | B M P 2 [Member]
Revenue from External Customer [Line Items]
Revenues		67	73
Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		60	60
Internal Medicine [Member] | Biopharma [Member] | All Other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues		639	730
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	1,961	1,760
Oncology [Member] | Biopharma [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		1,133	933
Oncology [Member] | Biopharma [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		232	262
Oncology [Member] | Biopharma [Member] | Xtandi Alliance [Member]
Revenue from External Customer [Line Items]
Revenues		168	159
Oncology [Member] | Biopharma [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		123	153
Oncology [Member] | Biopharma [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		80	60
Oncology [Member] | Biopharma [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		73	74
Oncology [Member] | Biopharma [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		153	119
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	1,887	2,026
Hospital [Member] | Biopharma [Member] | Other Anti-infectives [Member]
Revenue from External Customer [Line Items]
Revenues		354	392
Hospital [Member] | Biopharma [Member] | Other Hospital Products [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	631	708
Hospital [Member] | Biopharma [Member] | CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	176	171
Hospital [Member] | Biopharma [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	104	101
Hospital [Member] | Biopharma [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues		66	52
Hospital [Member] | Biopharma [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		177	168
Hospital [Member] | Biopharma [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	120	136
Hospital [Member] | Biopharma [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		60	70
Hospital [Member] | Biopharma [Member] | Tazosyn / Zosyn [Member]
Revenue from External Customer [Line Items]
Revenues		51	61
Hospital [Member] | Biopharma [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	85	98
Hospital [Member] | Biopharma [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	64	68
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,612	1,463
Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,486	1,380
Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		126	83
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	1,037	1,013
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		451	506
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		423	326
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Eucrisa [Member]
Revenue from External Customer [Line Items]
Revenues		22	26
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | All Other Inflammation and Immunology Products [Member]
Revenue from External Customer [Line Items]
Revenues		3	11
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues		138	145
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		470	549
Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		125	147
Rare Disease [Member] | Biopharma [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		107	132
Rare Disease [Member] | Biopharma [Member] | ReFacto AF/ Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		106	130
Rare Disease [Member] | Biopharma [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		59	63
Rare Disease [Member] | Biopharma [Member] | All Other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		72	76
Upjohn [Member] | Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[3],[9]	3,075	3,120
Upjohn [Member] | Upjohn [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues		1,186	1,213
Upjohn [Member] | Upjohn [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		622	511
Upjohn [Member] | Upjohn [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		300	256
Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		62	72
Upjohn [Member] | Upjohn [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues		145	187
Upjohn [Member] | Upjohn [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		77	71
Upjohn [Member] | Upjohn [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		69	74
Upjohn [Member] | Upjohn [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues		440	591
Upjohn [Member] | Upjohn [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		174	145
Consumer Healthcare [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	$ 858	$ 905
[1]	Amounts may not add due to rounding.
[2]	The Pfizer Biopharmaceuticals Group encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Hospital. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne(f).
[3]	We reclassified certain products from the Legacy Established Products (LEP) category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 product revenues to the current presentation.
[4]	We performed certain reclassifications in the All other Oncology category to conform 2018 product revenues to the current presentation.
[5]	Hospital is a new business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy Sterile Injectables Pharmaceuticals (SIP) category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 product revenues to the current presentation. Hospital also includes Pfizer CentreOne(f). All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
[6]	Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[7]	2018 revenues for Medrol, Zithromax, Vfend and Zyvox may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.
[8]	We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2018 product revenues to the current presentation.
[9]	Pfizer’s Upjohn business encompasses primarily off-patent branded and generic established medicines that includes 20 of our primarily off-patent solid oral dose legacy brands including Lyrica, Lipitor, Norvasc, Celebrex and Viagra, as well as certain generic medicines.
[10]	Pfizer’s Consumer Healthcare business is an over-the-counter medicines business, which we announced in December 2018 will be contributed to, and combined with, GSK’s consumer healthcare business to form a new consumer healthcare joint venture, of which we will own 32%, subject to customary closing conditions, including GSK shareholder approval, which occurred on May 8, 2019, and required regulatory approvals.

Segment, Geographic and Other_9

Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details) - brand	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2019
GSK Consumer Healthcare [Member] | Forecast [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		32.00%
Upjohn [Member] | Upjohn [Member]
Schedule of Equity Method Investments [Line Items]
Number of off-patent legacy brands	20